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bs in past years, this Highlights article takes the place of the
ditor’s Page, and was assembled by the Associate Editors
n the basis of the manuscripts that they perceived had or
ould have the greatest impact upon cardiology. Space
onstraints result in omitting many excellent manuscripts,
nd we apologize in advance to the authors.
oronary Artery Disease
T-segment elevation myocardial infarction (STEMI).
s the metric of door to balloon time (DBT) of great impor-
ance in patients who present late in the course of their
TEMI? Theoretically, with less muscle to salvage, late
resentations may negate the benefit of a short DBT. Using
ata from the CADILLAC (Controlled Abciximab and
evice Investigation to Lower Late Angioplasty Compli-
ations) and the HORIZONS-AMI (Harmonizing Out-
omes With Revascularization and Stents in Acute Myo-
ardial Infarction) trials, Brodie et al. (1) document that in
he subgroup of patients with late presentations (90 min
rom onset of pain), long DBT was no longer associated
ith a lower mortality. Both high-risk and low-risk patients
n the early presentation group benefited from a short DBT,
ut the absolute benefit was greatest in the high-risk patients
3.7% vs. 7.0% for short DBT vs. long DBT) compared with
ow-risk patients (0.8% vs. 1.5%).
One approach to reduce treatment delays is to initiate
herapy in the pre-hospital setting. The On-TIME 2
Ongoing Tirofiban in Myocardial Infarction Evaluation
) trial evaluated the use of high-dose glycoprotein IIb/IIIA
nhibitor tirofiban in the ambulance (2). The trial had an
pen label phase 1 followed by a double-blind phase 2; the
rimary endpoint of the pooled analysis was death, recurrent
yocardial infarction (MI), and urgent target vessel revas-
rom the *Cardiology Division, UCSD Medical Center, San Diego, California;
Leiden University Medical Center, Leiden, the Netherlands; ‡University of Min-
esota, Minneapolis, Minnesota; §Stanford University, Stanford, California; Veter-
ns Affairs Medical Center, San Diego, California; ¶Johns Hopkins Hospital,
altimore, Maryland; #Department of Cardiology, Cleveland Clinic, Cleveland,r
hio; and **Pediatric Cardiology, Oregon Health and Science University, Portland,
regon.ularization (TVR) at 30 days. During the 3 years of the
rial, 1,398 patients were treated, 414 in the open label
hase and 984 in the double-blind phase. Major adverse
ardiac events (MACE) at 30 days were significantly re-
uced by high-dose tirofiban (5.8% vs. 8.6%, p  0.043)
ith a trend toward a reduction in mortality (2.25% vs.
.1%, p  0.051). There was no increase in bleeding noted.
While pre-hospital administration of lytics and adjunct
herapies may improve time to reperfusion, patient delays in
alling 911 still average more than 2 h. A novel approach to
educe this delay was reported by Fischell et al. (3), who
mplanted an intracardiac ST-segment monitoring device in
7 patients who were at high risk for acute coronary
yndromes. The implanted device, similar to a pacemaker,
ontinuously monitored the ST segments from the right
entricular apical lead. Patients were alerted with an alarm
hen ST-segment elevations were noted of 3 SDs or more
f their regular daily range. Over a median follow-up of 1.52
ears, 4 patients had appropriate alarms, which led to very
apid presentation to the hospital of 19.5 min. An addi-
ional 4 patients had alarms at elevated heart rates, which
ere determined to be related to flow-limiting lesions.
hree patients had false positive alarms. This novel ap-
roach may be practical in patients already receiving a
acemaker/defibrillator.
leeding. Since bleeding during treatment of acute coro-
ary syndrome (ACS), primarily invasive treatment, is a
ignificant risk factor for mortality, it is important to predict
he risk of this complication. Using data from the ACUITY
Acute Catheterization and Urgent Intervention Triage
trategy Trial) and the HORIZONS-AMI trials, Mehran
t al. (4) developed a simple 7-variable risk score consisting
f female sex, advanced age, elevated serum creatinine and
hite cell count, anemia, non-STEMI, or STEMI, as well
s the use of heparin plus a IIb/IIIa inhibitor. Moreover, the
isk score identified patients at risk not only for 30-day rate
f non–CABG-related major bleeding but also 1-year
ortality. The score ranged from 0 (0.9% risk of major
leeding within 30 days) to 40 (43.5% bleeding risk). The
isk score may allow for tailoring percutaneous coronary
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January 25, 2011:480–514 Highlights From JACC 2010ntervention (PCI) procedures (such as with the use of radial
pproach rather than femoral approach) to lower the bleed-
ng risk. Whether such an approach would reduce mortality
emains to be proven.
isk factors and risk assessment. Optimal assessment of
ardiovascular (CV) risk continues to be controversial.
here different studies have reached varying conclusions
uch as metabolic syndrome, the use of meta-analysis may
e helpful. Mottillo et al. (5) performed a meta-analysis of
7 studies, involving 951,083 patients (approximately one-
alf using the 2001 National Cholesterol Education Pro-
ram definition and half using the 2004 revised definition
or the metabolic syndrome). The metabolic syndrome was
ound to be associated with a relative risk of 2.35 for CV
isease, 2.02 for CV disease mortality, 1.58 for total
ortality, 2.99 for MI, and 2.27 for stroke risk. Whether
he risk associated with the metabolic syndrome is greater
han the sum of its parts remains unclear.
Abdominal obesity is a key component of the metabolic
yndrome. The question of whether a modest increase in
bdominal fat is deleterious was assessed by Romero-Corral
t al. (6) using the surrogate endpoint of endothelial
ysfunction. They recruited 43 normal weight and healthy
olunteers who were then randomly assigned to a weight
ain group. Endothelial function measured by flow-
ediated dilation decreased (9.1  3% vs. 7.8  3.2%, p 
.003) with an average weight gain of 4.1 kg, but recovered
hen the subjects lost the weight again.
While low-density lipoprotein (LDL) cholesterol has
een the primary lipid risk factor and target of therapy in
arious guidelines, increasing attention has been paid to
ther lipid parameters. Non– high-density lipoprotein
HDL) cholesterol is an attractive measure and target as it
uantifies the cholesterol in all the known atherogenic
holesterol particles, including very low-density lipoprotein
VLDL), intermediate-density lipoprotein, and chylomi-
ron remnants. Arsenault et al. (7) reported 21,488 men and
omen without diabetes mellitus or coronary disease be-
ween the ages of 45 and 79 years followed up for 11 years
n the European Prospective Investigation Into Cancer and
utrition-Norfolk population study. Even among subjects
ith low LDL cholesterol levels (100 mg/dl), an elevated
on-HDL cholesterol 130 mg/dl was associated with a
azard ratio (HR) of 1.84 compared with non-HDL cho-
esterol 130 mg/dl. Total cholesterol/HDL cholesterol
nd elevated triglycerides were also associated with in-
reased risk.
Moderate alcohol consumption has been shown to be
ssociated with reduced CV and overall mortality. Whether
lcohol consumption has similar associations in secondary
revention populations is less clear. Costanzo et al. (8)
erformed a meta-analysis of 8 selected studies, which
ncluded 16,351 patients. They found that in a secondary
revention population there was a J curve with maximal
rotection for CV mortality by consuming 26 g/day, with a mower consumption in the range of 5 to 10 g/day having the
owest overall mortality.
The use of imaging to identify asymptomatic atheroscle-
osis and further risk stratify patients evaluated for primary
revention continues to generate intense interest as well as
ebate (9,10). Nambi et al. (11), reporting on data from the
RIC (Atherosclerosis Risk In Communities) study, as-
essed whether carotid intima-media thickness (CIMT) and
arotid plaque, alone or in combination, improved risk
tratification based on traditional coronary heart disease
CHD) risk factors. Of 13,145 subjects, close to a one-quarter
ere reclassified by adding CIMT plus plaque information,
ith an improvement in the area under the curve from 0.742 to
.755. The net reclassification index was highest at 9.9% when
oth the CIMT and presence of plaque were added to the
raditional CHD risk factors. The findings of the study add
o an increasing body of literature supporting the incorpo-
ation of carotid imaging in intermediate risk patients, and
re particularly timely given the upcoming National Cho-
esterol Education Program Adult Treatment Panel IV
eport (12).
While carotid imaging with intima media thickness
IMT) may play a role in baseline risk assessment, it has also
een proposed as a surrogate endpoint for CV events in
arious intervention trials such as lipid-lowering therapy.
ostanzo et al. (13 ), therefore, performed a meta regression
nalysis of randomized trials assessing IMT regression with
eduction in CV effects. They included 41 trials enrolling
8,307 participants. Despite significant reduction in CV
vents and all-cause death with active treatments, surpris-
ngly there was no significant relationship between IMT
egression and CHD events. These findings raise doubt as
o the suitability of IMT regression as a surrogate endpoint
n CV trials.
Endothelial dysfunction is an early event in the progres-
ion of atherosclerosis, and therefore may also have a role in
isk stratification. The traditional modality of brachial artery
eactivity (flow-mediated dilation [FMD]) is technically
hallenging, however, and has not gained routine clinical
se. Matsuzawa et al. (14), used a simpler and less user-
perated commercial device, the Endopat 2000 (Itamar,
esarea, Israel), which utilizes a finger plethysmograph
ather than ultrasound measurement of the brachial artery.
he reactive hyperemia peripheral artery tonometry (RH-
AT) measured by the device has been shown to correlate
ith FMD and with coronary endothelial dysfunction, and
mpaired RH-PAT was predictive of ischemic events in
omen. They further found that compared with the Reyn-
lds Risk Score, RH-PAT was more predictive for nonob-
tructive coronary artery disease (CAD).
While smoking has been well recognized as a potent CV
isk factor for decades, the impact of secondhand smoke
SHS) has been less well defined, and the associated
echanisms have not been fully understood. Hamer et al.
15) studied 13,443 subjects in England and Scotland and
easured salivary cotinine, an objective marker of exposure
t
m
(
C
a
a
s
c
s
w
t
w
s
A
c
t
n
L
t
d
i
c
e
a
d
c
a
T
t
(
t
p
t
a
r
o
n
c
i
w
w
P
i
w
i
p
g
c
t
S
h
a
g
t
(
t
i
s
r
a
p
r
t
t
t
f
p
A
2
p
p
P
l
a
b
f
(
a
c
a
l
o
e
t
a
d
d
m
t
u
i
a
w
r
i
c
p
o
a
a
c
c
a
c
482 DeMaria et al. JACC Vol. 57, No. 4, 2011
Highlights From JACC 2010 January 25, 2011:480–514o SHS. Exposure to SHS was associated with all-cause
ortality (HR: 1.21) and elevated C-reactive protein
CRP), linking inflammation as a mediator of SHS-related
V disease. Not all studies on smoking have confirmed an
ssociation with CRP. In a study from Japan, Tomiyama et
l. (16) studied 2,054 subjects who were divided by their
moking status. Over a 5- to 6-year follow-up period, the
ontinuous heavy smokers had significantly greater progres-
ion of arterial stiffening as judged by brachial-ankle pulse
ave velocity. There was no relationship found, however, in
hat study with serum CRP levels.
The benefits of smoking cessation on vascular function
as assessed by Johnson et al. (17) in a study of 1,504
mokers enrolled in various smoking cessation therapies.
mong those who successfully quit smoking (36.2% of the
ohort), there was a 1% improvement in FMD (6.2  4.4%
o 7.2 4.2%), whereas those who continued smoking had
o change in FMD.
ipid-lowering therapy. While statins are likely to remain
he cornerstone of lipid-lowering therapy, attempts to
evelop novel antilipidemic drugs continue. One approach
s to inhibit the production of apolipoprotein B (apo-B), the
arrier protein of atherogenic particles such as LDL. Akdim
t al. (18) reported on the efficacy and safety of mipomersen,
n antisense inhibitor of apo-B synthesis. In their phase 2
ose-escalation study, 74 subjects were enrolled into 6 dose
ohorts, from 30 to 400 mg. The LDL cholesterol and
po-B were reduced by up to 52% and 54%, respectively.
he drug, which is injected once weekly, caused some mild
o moderate erythema. Importantly, there was a very high
50%) incidence of liver enzyme elevation in a group given
he drug for 13 weeks.
The safety of statins, and particularly whether they may
ose a cancer risk, has been the subject of much investiga-
ion and debate. Important additional data in this area were
dded by Gränsbo et al. (19), using a Swedish acute MI
egistry, with data on 21,410 patients 80 years of age and
lder. Using propensity analysis, they demonstrated a sig-
ificant reduction in all-cause mortality without any in-
rease in cancer mortality. These data are particularly
nteresting as it points to the benefit of statin treatment
ithout increased cancer mortality in an elderly population
ith a high risk of cancer.
latelets and antiplatelet therapies. The role of platelets
n acute coronary syndromes and post-PCI complications as
ell as the complex area of response to clopidogrel and its
nteractions with other drugs (and the contribution of
olymorphisms to these interactions) continued to generate
reat interest in 2010.
Whether a rebound phenomenon exists upon cessation of
lopidogrel is a key question, as guidelines suggest discon-
inuing clopidogrel after 1 year of therapy after DES.
ibbing et al. (20) randomly assigned 65 patients about to
ave clopidogrel stopped to either a tapering regimen or
brupt discontinuation. The authors measured platelet ag-
regation using light transmission aggregometry and mul- giple electrode aggregometry. Adenosine diphosphate
ADP)-induced platelet aggregation was no different be-
ween the abrupt cessation and the tapering group, suggest-
ng that rebound did not exist.
Lev et al. (21) identified 30 patients (of 485 initially
creened) receiving 75 to 182 mg daily who were “aspirin
esistant” and randomly allocated them to either 325 mg of
spirin or to the addition of omega-3 fatty acids. The
atients were retested after 30 days. They found significant
eductions in arachidonic acid and ADP-induced aggrega-
ion as well as in the VerifyNow score in both groups, with
he majority in both groups no longer being aspirin resis-
ant. Gajos et al. (22) similarly studied the effect of omega-3
atty acids on platelet activation in patients on dual anti-
latelet agents (aspirin and clopidogrel) undergoing PCI.
fter 1 month of treatment, platelet reactivity as assessed by
0 mol/l ADP was reduced by 13.3% (p  0.026).
One of the limitations of clopidogrel is that the drug is a
rodrug, which requires activation through the cytochrome
450 system (CYP2C19) and is prone to polymorphisms.
rasugrel, while also a prodrug is more efficiently metabo-
ized and produces greater, more rapid platelet inhibition,
nd reduced ischemic events but at an increased risk of
leeding. The pharmacodynamics of switching patients
rom clopidogrel to prasugrel was assessed in the SWAP
Switching Antiplatelet) study (23). The 139 patients with
recent ACS event were first treated with open label
lopidogrel for 10 to 14 days, and were then randomly
ssigned to continued clopidogrel, prasugrel loading fol-
owed by maintenance prasugrel, or prasugrel maintenance
nly without a loading dose. Overall, prasugrel was more
ffective in achieving platelet inhibition than clopidogrel—
he added platelet inhibition was evident at 1 week without
loading dose of prasugrel and within 2 h with a loading
ose.
In ACS patients undergoing diagnostic angiography
eemed to require coronary surgery, prior clopidogrel treat-
ent may increase bleeding risk, prompting many surgeons
o delay surgery for several days. Shim et al. (24) studied the
se of a modified thromboelastography in predicting bleed-
ng and need for transfusion in 100 recipients of clopidogrel
waiting coronary artery bypass graft surgery (CABG)
ithin 5 days since their last dose of clopidogrel. They
eport that irrespective of time from last clopidogrel admin-
stration, high levels of platelet inhibition predicted in-
reased blood loss and transfusion requirement after off-
ump CABG, with a cut-off value of 70% for increased risk
f transfusion. The use of the thromboelastography test may
llow tailored timing of surgery to minimize bleeding risk
nd surgical delay.
Once a patient undergoes CABG is there a role for
lopidogrel therapy? Gao et al. (25) randomly allocated 249
onsecutive elective CABG patients to aspirin alone or to
spirin and clopidogrel therapy after CABG. Multislice
oronary angiography was performed at 3 months. Vein
raft patency was greater (91.6%) in the aspirin and clopi-
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January 25, 2011:480–514 Highlights From JACC 2010ogrel group than in the aspirin-alone group (85.7%, p 
.043). Longer-term studies are now needed.
Assessment of high risk for CABG remains challenging.
hile frailty is a well-recognized risk factor for poor
utcomes, its objective assessment is difficult. Afilalo et al.
26) conducted a multicenter prospective study of 131
lderly patients undergoing coronary bypass surgery and/or
alve replacement. They tested the predictive value of slow
ait speed, defined as a time taken to walk 5 m of 6 s. The
rimary endpoint was a composite of in-hospital postoper-
tive mortality or major morbidity. Slow gait speed was an
ndependent predictor of the composite endpoint even after
djusting for the Society of Thoracic Surgeons risk score
odds ratio [OR]: 3.05).
ypertension and arterial stiffness. Pre-hypertension, de-
ned as 120 to 139 systolic or 80 to 89 mm Hg diastolic, is
ommon and increases with age. Whether changes in body
omposition, namely, weight gain or weight loss as well as
at gain or loss, influence the progression or regression of
ypertension in pre-hypertensive persons was examined by
arkus et al. (27) in a cohort of 1,145 subjects from the
ONICA/KORA (Monitoring Trends and Determinants
n Cardiovascular Diseases/Cooperative Research in the
egion of Augsburg) cohort study. They followed up the
roup over 10 years. Subjects who had progression to
ypertension (one-half the cohort) were characterized by
eight gain, principally due to fat gain, while the small
ercentage (6.76%) who went from being hypertensive to
re-hypertensive were characterized by decrease in body
eight and fat mass.
Resistant hypertension is a vexing problem in clinical
are. Scheffers et al. (28) report on the use of a novel
mplantable device (Rheos System, CVRx, Inc., Minneap-
lis, Minnesota) that works by electrical stimulation of the
arotid sinus, thereby causing baroreflex activation. Study-
ng 45 patients with resistant hypertension, they report a
eduction in mean blood pressure of 21/12 mm Hg at 3
onths. Although the study was not randomized, when the
evice was turned off, there was a prompt increase in blood
ressure. Further study is clearly warranted for such non-
harmacologic approaches, which may be practical for the
ost difficult to treat patients.
Various publications over the past year assessed the
ontribution of arterial stiffness to the prediction of CV
vents, as well as the utility of the various measurements
eflective of arterial stiffness.
Vlachopoulos et al. (29) performed a systematic review
nd meta-analysis of studies looking at the predictive value
f aortic pulse wave velocity (PWV) for CV events and
ll-cause mortality. Using data from 17 studies (total of
5,877 subjects followed up for a mean of 7.7 years), they
howed that the pooled relative risks (RR) for clinical events
ncreased in a linear fashion across tertiles of PWV, includ-
ng an almost doubling of risk of total mortality. An increase
f 1 SD in aortic PWV was associated with an increase in Uotal CV events, CV mortality, and all-cause mortality of
7%, 47%, and 42%, respectively.
Benetos et al. (30) reported on a novel hemodynamic
iomarker for CV risk, which they termed pulse pressure
mplification. Normally central (carotid) pulse pressure is
ower than brachial blood pressure. With aging, there is a
isproportionate increase in central aortic stiffness, which
uts an increased load on the heart. The result is an increase
n central pulse pressure amplification compared with bra-
hial. This parameter can be quantified as the carotid/
rachial ratio. The authors first derived a normogram
elating measured brachial and carotid pulse pressure. They
hen applied this model to a population of 125,151 subjects
ho were followed up for 12 years. They found that the
arotid/brachial ratio was a strong predictor for both CV
nd total mortality (HR: 1.22, 95% confidence interval [CI]:
.12 to 1.32, and HR: 1.41, 95% CI: 1.14 to 1.73,
espectively).
idney disease. Widely accepted therapies such as anti-
latelet agents and statins may have different risk/benefit
rofiles in patients with chronic kidney disease (CKD). One
otentially novel mechanism was reported by Meyer et al.
31), who examined endothelial function in 14 hemodialysis
atients. They measured FMD before and after dialysis and
emonstrated a post-dialysis impairment of endothelial
unction, which correlated with release of hemoglobin
hemolysis). Moreover, the cell free hemoglobin led to a
ecrease in the bioavailability of free nitric oxide.
Jardine et al. (32) examined the effects of aspirin 75 mg
aily versus placebo in patients with diastolic hypertension
n the HOT (Hypertension Optimal Treatment) study who
ere stratified by glomerular filtration rate (GFR). The
uthors found an increasing benefit of aspirin treatment
ith decreasing renal function. Major CV events were
educed by 9%, 15%, and 66% in patients with baseline
stimated GFR of 60, 45 to 59, and45 ml/min/1.73 m2
p trend  0.03); total mortality was similarly lowered, and
ajor bleeding was nonsignificantly greater with lower
GFR. For every 1,000 patients with estimated GFR 45
l/min/1.73 m2 treated for 3.8 years, aspirin at 75 mg daily
revented 76 major CV events and 54 deaths, with only 27
xcess major bleeds.
Diabetes and CKD often coexist. Diabetes is also a risk
actor for high post-treatment platelet reactivity. Angiolillo
t al. (33) examined 306 diabetic patients and compared the
ntiplatelet effects of dual antiplatelet therapy (aspirin and
lopidogrel) in those with moderate and severe kidney
ysfunction to those with normal kidney function. Patients
ith moderate/severe kidney disease were 3.8 times more
ikely to have high post-treatment platelet reactivity than
ere patients with normal function.
The long-term results of several landmark clinical trials
egarding the treatment of ACS were reported this year.
amman et al. (34) reported the 5-year clinical outcomes of
he ICTUS (Invasive Versus Conservative Treatment in
nstable Coronary Syndromes) trial. They randomly allo-
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Highlights From JACC 2010 January 25, 2011:480–514ated 1,200 patients to an early invasive or selective invasive
trategy. At 5 years, cumulative death and MI rates were
2.3% and 18.1% in the early invasive and selective invasive
roups, respectively (p  0.053). However, no statistically
ignificant differences were observed in either mortality or
I. Thus, at 5 years, patients with non–ST-segment
levation ACS and elevated troponin T did not manifest a
ong-term benefit from an early invasive strategy in reducing
ither death or MI. In an accompanying editorial, Bittl and
aron (35) point out that most patients in either arm
nderwent diagnostic angiography. They further opine that
oth early invasive and delayed selective invasive strategies
ave values and limitations; the greatest importance of the
CTUS trial is that it demonstrates that an individualized
pproach can be undertaken in patients with non-STEMI.
In a related paper dealing with the issue of non-STEMI,
ox et al. (36) performed an interesting meta-analysis that
ncorporated the findings not only of the ICTUS trial, but
lso the 5-year outcomes from the FRISC2 (Fragment and
ast Revascularization During Instability in Coronary Ar-
ery Disease) trial and the RITA3 randomized trial of the
onservative treatment strategy versus an interventional
reatment strategy for patients with unstable angina. The
nclusion of 5,467 patients rendered significant as statistical
ower. Over 5 years, 14.7% of the patients randomly
ssigned to a routine invasive strategy experienced either
V death or nonfatal MI versus 17.9% in the selective
nvasive arm (p  0.002). The greatest effect was upon a
I, and there was a substantial benefit attributed to patients
n the highest risk category. Thus, when the results of the
CTUS trial was combined with those of 2 other similar
tudies, a routine invasive strategy appeared superior, al-
hough this was most dramatic in the highest-risk patients.
The role of plaque instability and thrombus formation in
he production of MI continues to evolve. Kramer et al. (37)
tudied coronary lesions from 111 sudden death victims
rom the medical examiner. In this group, 65 of the lesions
ere ruptures, whereas 50 were erosions. Interestingly, 69%
f all lesions associated with sudden death were found to
ave “late stage” organizing thrombi. These data suggest the
udden death may actually be a late stage complication of
laque instability and thrombosis, and perhaps may be
elated to microembolization. In an accompanying editorial,
evin (37a) comments that the distinction of plaque erosion
nd plaque rupture may allow for individualized therapy in
atients with CAD.
nterventional Cardiology
andomized Clinical Trials
he JETSTENT trial. The JETSTENT(AngioJet Rheo-
ytic Thrombectomy Before Direct Infarct Artery Stenting
n Patients Undergoing Primary PCI for Acute MI) trial
38), a multicenter, prospective study compared rheolytic
hrombectomy before direct infarct artery stenting to direct
tenting to improve myocardial reperfusion and MACE in p01 acute MI (AMI) patients with angiographic evidence of
hrombus grade 3 to 5 and a reference vessel diameter 2.5
m. Co-primary endpoints were early ST-segment resolu-
ion and 99mTc-sestamibi infarct size (p 0.05 for both or
 0.025 for 1 for significance). The ST-segment resolu-
ion was more frequent in the rheolytic thrombectomy
ersus the direct stenting alone arm (85.8% vs. 78.8%, p 
.043). Although no differences were noted in the other
urrogate endpoints, the 6-month MACE rate (11.2% vs.
9.4%, p  0.011) and 1-year event-free survival rates (85.2
s. 75.0, p  0.009) were improved with rheolytic throm-
ectomy. The authors suggest that, although the primary
fficacy endpoints were not met, the results support the use
f rheolytic thrombectomy before infarct artery stenting in
atients with AMI and evidence of coronary thrombus.
owever, an accompanying editorial suggested that in keeping
ith current guideline recommendations, thrombus extraction
eems to be a useful adjunctive therapy for patients undergoing
rimary PCI for STEMI, and the modality of choice appears
o be simple manual aspiration (39).
he ZEST trial. The ZEST (Comparison of the Efficacy
nd the Safety of Zotarolimus-Eluting Stent Versus
irolimus-Eluting Stent and Paclitaxel-Eluting Stent for
oronary Lesions) trial (40), a single-blind, multicenter,
rospectively randomized trial involving 2,645 patients un-
ergoing PCI evaluated the relative efficacy and safety of
otarolimus-eluting stents (ZES), sirolimus-eluting stents
SES), and paclitaxel-eluting stents (PES) for a composite
f MACE at 12 months. At 12 months, the ZES group
howed noninferior rates of MACE compared with the SES
roup (10.2% vs. 8.3%, p for noninferiority  0.01, p for
uperiority  0.17) and significantly fewer MACE than the
ES group (10.2% vs. 14.1%, p for superiority 0.01). The
ncidence of death or MI was similar among the groups.
he incidence of stent thrombosis was significantly lower in
he SES group (ZES vs. SES vs. PES, 0.7% vs. 0% vs. 0.8%,
espectively; p  0.02). In this large-scale, practical ran-
omized trial, the use of ZES resulted in similar rates of
ACE compared with SES, and fewer MACE compared
ith PES at 12 months.
he EVA-AMI trial. The EVA-AMI (Efficacy of Eptifi-
atide Compared With Abciximab in Primary PCI for
cute ST Elevation MI) trial (41) randomly allocated 427
atients with STEMI 12 h and planned primary PCI to
ouble-bolus eptifibatide followed by a 24-h infusion or
ingle-bolus abciximab followed by a 12-h infusion. In this
oninferiority trial, the primary endpoint was the incidence
f complete (70%) ST-segment resolution 60 min after
CI. The incidence of complete ST-segment resolution at
0 min after PCI in the intention-to-treat analysis was
2.6% after eptifibatide and 56.3% after abciximab, and rein-
arction was 0.4% versus 3.5%, respectively (p  0.03). All-
ause mortality, the combined endpoint of death, nonfatal
einfarction, TVR, after 6 months, and major bleeding com-
lications after 30 days were similar. In conclusion, eptifibatide
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ith respect to ST-segment resolution.
In the SCAAR (Swedish Coronary Angiography and
ngioplasty Registry) study (42), 11,479 STEMI patients
ho underwent primary PCI and received either eptifibatide
r abciximab were evaluated for the primary endpoint of
eath or MI during 1-year follow-up, with adjustment for
aseline differences with a multivariate logistic regression
nalysis including propensity score. The combined endpoint
ccurred in 15% treated with eptifibatide and 15.7% treated
ith abciximab, the unadjusted OR was 0.95 (95% CI: 0.84
o 1.08). Multivariate adjustment and the adjusted second-
ry endpoints of death and MI separately also showed
oninferiority. This large registry also supports that eptifi-
atide is noninferior to abciximab for patients with STEMI
ndergoing primary PCI.
he ISAR-DESIRE 2 trial. The ISAR-DESIRE 2 (In-
racoronary Stenting and Angiographic Results: Drug Elut-
ng Stents for In-Stent Restenosis 2) trial (43), randomly
llocated, open-label, 450 patients with clinically significant
n-SES restenosis to repeat SES versus PES. The primary
ndpoint was late lumen loss based on in-stent analysis at 6-
o 8-month follow-up angiography. There were no differ-
nces between SES and PES in late loss, binary restenosis,
arget lesion revascularization (TLR), death/MI, and stent
hrombosis, suggesting a comparable degree of efficacy and
afety.
he ENDEAVOR IV trial. The ENDEAVOR IV (Ran-
omized Comparison of Zotarolimus-Eluting and
aclitaxel-Eluting Stents in Patients With Coronary Artery
isease IV) trial (44) evaluated the safety and efficacy of
ES (n  773) compared with PES (n  775) in a
rospective, randomized, single-blind, controlled trial in
atients with single de novo coronary lesions. The primary
ndpoint was noninferiority of 9-month target vessel failure
TVF) defined as cardiac death, MI, or TVR. At 9 months,
ES was noninferior to PES regarding TVF, and fewer had
eriprocedural MIs (0.5% vs. 2.2%; p 0.007), although at 12
onths there were no significant differences between groups in
ates of cardiac death, MI, TVR, or stent thrombosis.
he LIPSIA-N-ACC trial. The LIPSIA-N-ACC (Myo-
ardial Salvage and Contrast Dye Induced Nephropathy
eduction by N-Acetylcysteine) trial (45), a randomized,
ingle-blind, controlled trial assessed N-acetylcysteine ef-
ects on contrast-induced nephropathy and reperfusion
njury in 251 STEMI patients undergoing primary PCI
ith moderate contrast volumes. Patients were randomly
llocated to either high-dose N-acetylcysteine (2  1,200
g daily for 48 h) or placebo plus optimal hydration. The 2
rimary endpoints were: 1) the occurrence of25% increase
n serum creatinine level 72 h after randomization; and
) a reduction in reperfusion injury measured as myocardial
alvage index by magnetic resonance imaging. The primary
ndpoint occurred in 14% of the N-acetylcysteine group and
n 20% of the placebo group (p  0.28). The myocardial
alvage index was also not different. High-dose intravenous fi-acetylcysteine does not provide an additional clinical
enefit to placebo in nonselected patients undergoing PCI,
lthough a larger study with more power may be indicated
o define the role of N-acetylcysteine in PCI.
he NORDISTEMI trial. The NORDISTEMI (Nor-
egian Study on District Treatment of ST-Elevation MI)
rial (46) compared immediate transfer for PCI with an
schemia-guided approach after thrombolysis in patients
ith very long transfer distances. A total of 266 patients
ith STEMI with 90-min transfer delays for PCI were
reated with tenecteplase, aspirin, enoxaparin, and clopi-
ogrel and randomly assigned to immediate transfer or to
tandard management in the local hospitals except clinical
eterioration. The primary outcome, a composite of death,
einfarction, stroke, or new ischemia at 12 months, was
eached in 21% patients in the early invasive group com-
ared with 27% in the conservative group. (p  0.19). The
omposite of death, reinfarction, or stroke at 12 months was
ignificantly reduced in the early invasive compared with the
onservative group (6% vs. 16%, p  0.01). No significant
ifferences in bleeding or infarct size were observed, perhaps
ecause of the high rate of radial access (80%). In
onclusion, immediate transfer for PCI reduced the rate of
eath, reinfarction, or stroke at 12 months among patients
ith STEMI treated with thrombolysis and clopidogrel in
reas with long transfer distances.
he ARMYDA-5 PRELOAD trial. The ARMYDA-5
RELOAD (Antiplatelet therapy for Reduction of Myo-
ardial Damage During Angioplasty) randomized trial (47)
valuated the safety and effectiveness of 600 mg clopidogrel
n laboratory loading before PCI (in-laboratory, n  205)
ersus 600 mg given 4 to 8 h before PCI (pre-load, n 
04). The primary endpoint, 30-day incidence of MACE,
as similar between groups (8.8% in-laboratory vs. 10.3%
re-load), and no difference in bleeding or vascular compli-
ations was observed. Thus, when indicated, in-laboratory
lopidogrel administration before PCI can be a safe alter-
ative to routine pre-treatment given before knowing pa-
ients’ coronary anatomy.
ollow-Up Studies of Randomized Clinical Trials
he FAME study. The FAME (Fractional Flow Reserve
ersus Angiography in Multivessel Evaluation) study (48)
nvestigated the relationship between angiographic and
unctional severity of coronary artery stenoses in 509 pa-
ients with multivessel CAD in the fractional flow reserve
FFR)-guided arm of the FAME study. Before FFR mea-
urement, these lesions were categorized into 50% to 70%
iameter stenosis (47% of all lesions), 71% to 90% diameter
tenosis (39% of all lesions), and 91% to 99% diameter
tenosis (15% of all lesions) by visual assessment. A total of
5%, 80%, and 96% stenosis were functionally significant
FFR 0.80) in the category 50% to 70%, 71% to 90%, and
0% to 91%, respectively. In stenoses, 96% were functionally
ignificant. Of all 509 patients with angiographically de-
ned multivessel disease, only 46% had functional multives-
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Highlights From JACC 2010 January 25, 2011:480–514el disease by FFR. This study suggests that angiography is
naccurate in assessing the functional significance of a
oronary stenoses in the 50% to 90% range.
The principle investigators of the FAME trial also
eported their 2-year follow-up results comparing FFR
ersus angiography to guide PCI in patients with multives-
el CAD (49). Combined rates of death and MI were 12.9%
n the angiography-guided group and 8.4% in the FFR-
uided group (p  0.02). Differences between these ap-
roaches were not statistically significant when revascular-
zation was added. Thus, these data indicate that routine
easurement of FFR in patients with multivessel CAD
ndergoing PCI with drug-eluting stents reduces mortality
nd MI at 2 years compared with a standard angiography-
uided PCI.
he DEDICATION trial. The DEDICATION (Drug
lution and Distal Protection in ST Elevation MI) trial
50) evaluated the long-term effects of distal protection
uring PCI for STEMI patients assigned to distal protec-
ion (n  312) or conventional treatment (n  314). The
otal number of stent thromboses was 11 in the distal
rotection group and 4 in the conventional treatment group
p  0.06). In primary PCI for STEMI, the routine use of
istal protection increased the incidence of definite stent
hrombosis and clinically driven TLR/TVR during 15
onths of follow-up. Although the events rates are low and
he study needs to be confirmed, the results does suggest
hat additional vessel manipulation by distal protection
evices may lead to increased MACE in native coronary
essels.
he SESAMI trial. The SESAMI (Sirolimus-Eluting
tent Versus Bare-Metal Stent In Acute MI) trial (51)
nvestigated whether the reported favorable 1-year MACE
ncidence of SES versus BMS in 320 STEMI patients was
aintained at 3-year follow-up. The 3-year incidence of
ACE was lower in the SES group compared with the
MS group (12.7% vs. 21%, p  0.034), as were TLR,
VR, and TVF rates. The 3-year survival rate free from
ACE, TLR, and TVF was significantly higher in the SES
roup than in the BMS group. The lower incidence of
dverse events in the SES group was driven by TLR
eduction and achieved in the first year of follow-up. The
umulative incidence of death and recurrent MI, starting
rom clopidogrel discontinuation, was comparable in the 2
roups.
he ACUITY trial. The ACUITY (Acute Catheteriza-
ion and Urgent Intervention Triage Strategy) trial (52)
valuated the impact of delay to PCI in 7,749 patients with
on–ST-segment elevation ACS at a median of 19.5 h after
resentation. Delay to PCI24 h after clinical presentation
as significantly associated with increased 30-day mortality,
I, and composite ischemia (death, MI, and unplanned
evascularization). By multivariable analysis, delay to PCI
f 24 h was a significant independent predictor of 30-day
nd 1-year mortality, and risk was greatest for high-risk
atients. These findings suggest that angiography and triage Ao revascularization within 24 h should be a priority in
on–ST-segment elevation ACS patients.
he SYNTAX trial. The SYNTAX (Synergy Between
ercutaneous Coronary Intervention With Taxus And Car-
iac Surgery) trial in patients with symptomatic left main
nd/or 3-vessel disease demonstrated that bypass surgery
nd percutaneous intervention with Taxus stents yielded
omparable results for death and MI, but a higher stroke
ate for surgery and higher repeat revascularization rate for
CI. Banning et al. (53) reported the results of the Taxus
rial in the pre-specified subgroup with diabetes mellitus. In
52 patients with diabetes, the 1-year major adverse cardiac
nd cerebral vascular event rate was higher when treated
ith paclitaxel stents than with bypass surgery, a difference
ue to a greater rate of repeat revascularization. However,
he rate of hard events (death, MI, or stroke), was similar for
he 2 treatment approaches. In an accompanying editorial,
auerman (54) opines that these results indicate that, in
iabetic patients with left main or triple-vessel disease, PCI
ith paclitaxel-eluting stents is not associated with in-
reased mortality, as was true of bare metal stents, and may
e undertaken in patients judged to be poor candidates for
ypass surgery.
he HORIZONS AMI trial. The HORIZONS-AMI
Harmonizing Outcomes With Revascularization and
tents in Acute Myocardial Infarction) trial randomly as-
igned 3,000 patients with STEMI to either paclitaxel-
luting stents or BMS (55). At 24 months of follow-up,
LR continued to be less with the PES than with BMS.
mportantly, insulin-treated diabetes, reference vessel diam-
ter 3.0 mm, and lesion length 30 mm were indepen-
ent predictors of 12-month TLR with BMS. In patients
ith 2 or 3 of these risk factors, PES markedly reduced
2-month TLR, but no difference between PES and BMS
xisted for patients with no risk factors. Thus, in patients
ith STEMI, PES is of benefit in reducing TLR in patients
ith risk factors, but not in lower risk patients.
he ISAR-TEST 2 trial. Byrne et al. (56) reported the
-year clinical and angiographic outcomes of the ISAR-
EST-2 (Intracoronary Stenting and Angiographic Re-
ults: Test Efficacy of 3 Limus-Eluting Stents) trial. In a
andomized trial, they compared sirolimus, a new genera-
ion sirolimus and probucol-eluting stent, with zotarolimus-
luting stent (56). Probucol was added to sirolimus to target
different element of the restenotic process well as to retard
he release of the sirolimus by virtue of lipophilicity. At
-year follow-up, the drugs were found to have comparable
afety profiles whereas the dual sirolimus/probucol stent
anifested a greater reduction of TLR than the sirolimus
tent, but comparable to that of the Endeavor instrument.
egistry Studies
he MAIN-COMPARE registry. The MAIN-COMPARE
Revascularization for Unprotected Left Main Coronary
rtery Stenosis: Comparison of Percutaneous Coronary
ngioplasty Versus Surgical Revascularization) registry (57)
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January 25, 2011:480–514 Highlights From JACC 2010valuated 2,240 patients with unprotected left main coro-
ary artery disease who received coronary stents (n 1,102;
18 with BMS) or underwent CABG (n  1,138) between
000 and 2006, and for whom complete follow-up data
ere available for at least 3 to 9 years (median 5.2 years).
fter adjustment for differences in baseline risk factors with
he inverse probability of treatment weighting, the 5-year
isk of death (HR: 1.13; p 0.35) and the combined risk of
eath, Q-wave MI, or stroke (HR: 1.07; p 0.59) were not
ignificantly different. The risk of TVR was significantly
igher in the stenting group than in the CABG group (HR:
.11; p  0.001). Similar results were obtained in compar-
sons of BMS with concurrent CABG and of DES with
oncurrent CABG.
he ASAN-MAIN registry. The ASAN-MAIN (ASAN
edical Center–Left Main Revascularization) registry (58)
valuated the long-term safety and effectiveness of PCI
ompared with CABG for unprotected left main coronary
rtery disease in a 10-year clinical follow-up of 350 patients
ho underwent PCI with BMS or CABG (n  250) and
-year clinical follow-up of 395 patients with DES or
ABG (n  219). In the 10-year follow-up cohort of BMS
nd concurrent CABG, the adjusted risks of death and the
omposite of death, Q-wave MI, or stroke were similar
etween the 2 groups. The rate of TVR was significantly
igher in the group that received BMS (HR: 10.34; p 
.001). In the 5-year follow-up cohort of DES and concur-
ent CABG, there was no significant difference in the
djusted risk of death or the composite outcome. The rates
f TVR were also higher in the DES group than the CABG
roup (HR: 6.22; p  0.001). This registry of long-term
utcomes of unprotected left main coronary artery disease
uggests that PCI with stent implantation is associated with
imilar long-term mortality and rates of death, Q-wave MI,
r stroke but higher rates of repeat revascularization than
ABG for both BMS and DES.
he ARTS II study. The ARTS II (Arterial Revascular-
zation Therapies Study II) study (59) compared the 5-year
linical outcomes, safety, and efficacy of SES with the
utcomes of CABG and BMS from the ARTS I study. The
RTS I study was a randomized trial of 1,205 patients with
ultivessel disease comparing CABG and BMS. The
RTS II study was a nonrandomized trial with the SES,
pplying the same inclusion and exclusion criteria, end-
oints, and protocol definitions. At 5 years, the death/
troke/MI event-free survival rate was 87.1% in the ARTS
I SES cohort, versus 86.0% (p  0.1) and 81.9% (p 
.007) in the ARTS I CABG and BMS cohorts, respec-
ively. The 5-year major adverse cardiac and cerebrovascular
vent rate in the ARTS II study (27.5%) was significantly
igher than the ARTS I study CABG (21.1%, p  0.02),
nd lower than in the ARTS I study BMS (41.5%, p 
.001). The cumulative incidence of definite stent throm-
osis was 3.8%. Thirty-two percent (56 of 176) of MACE
t 5 years was related to possible, probable, or definite stent
hrombosis. ghe COBIS registry. The COBIS (Coronary Bifurcation
tenting) registry (60) compared the long-term clinical
utcomes of 1,033 patients treated with SES and 562
atients treated with PES for coronary bifurcation lesions.
reatment with SES was associated with a lower incidence
f MACE (HR: 0.53, p  0.01) and TLR (HR: 0.55, p 
.02), but not of cardiac death and cardiac death or MI.
fter propensity-score matching, patients with SES still
ad fewer MACE and lower TLR incidence than did
atients with PES (HR: 0.52, p  0.02, and HR: 0.48, p 
.02, respectively). There was no significant difference in the
ccurrences of stent thrombosis between the groups (0.7%).
n patients with bifurcation lesions, the use of SES resulted
n better long-term outcomes than did the use of PES,
rimarily by decreasing the rate of repeat revascularization.
In a pathology study of 40 stented bifurcation lesions (21
MS and 19 DES), plaque formation in native coronary
ifurcations and neointimal growth after DES implantation
as significantly less at the flow divider versus the lateral
all (61). A higher prevalence of late stent thrombosis in
ES compared with BMS was associated with greater
ncovered struts at flow divider sites, which is likely due to
ow disturbances.
o-reflow phenomenon. Ndrepepa et al. (62) investigated
he impact of no-reflow phenomenon by angiography on
-year mortality among 1,406 patients with STEMI treated
y primary PCI. Infarct size measured with single-photon
mission computed tomography imaging 7 to 14 days after
he acute event was 15.0% of the left ventricle in the
o-reflow group versus 8.0% in the reflow group (p 
.001). There were 59 deaths among patients with no-
eflow and 73 deaths among patients with reflow (p 
.001). The Cox proportional hazards model adjusting for
nfarct size among other variables identified the no-reflow
henomenon as an independent correlate of 5-year mortal-
ty (HR: 1.66, p  0.004). The no-reflow phenomenon
fter PCI provides prognostic information that is indepen-
ent of and beyond that provided by infarct size.
ytochrome CYP2C19 polymorphism and antiplatelet
ffects of clopidogrel. Hochholzer et al. (63) evaluated the
mpact of demographic and clinical variables versus the
ytochrome P450 2C19 (CYP2C19) polymorphism on an-
iplatelet effects of clopidogrel in 760 patients undergoing
lective PCI after loading with 600 mg of clopidogrel.
ajor independent predictors for an insufficient antiplatelet
esponse to clopidogrel were CYP2C19*2 carrier status (OR:
.74), together with age (OR: 1.03), diabetes mellitus (OR:
.75), and body mass index (BMI) (OR: 1.06). Classifica-
ion and regression trees analyses demonstrated that
YP2C19*2 carrier status followed by diabetes mellitus was
he best discriminator between a sufficient and an insuffi-
ient antiplatelet response to clopidogrel. A full linear
egression model including all these parameters could only
xplain 11.5% of the antiplatelet response (5.2% by
YP2C19*2 carrier status alone). This study suggests that
enotyping alone or in combination with clinical factors
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lopidogrel.
arotid and Peripheral Arterial Disease Stenting
roximal endovascular occlusion for carotid artery stenting.
tabile et al. (64), in a single-center registry, evaluated
roximal endovascular occlusion in 1,300 patients undergo-
ng carotid artery stenting. Patients received an independent
eurological assessment before the procedure and 1 h, 24 h,
nd 30 days after the procedure. Procedural success was
chieved in 99.7% of patients. The 30-day stroke and death
ncidence was 1.38% (n  19) and was greater in symptom-
tic patients (3.04% vs. 0.82%; p 0.05). The 30-day stroke
nd death rate was similar among patients at high and
verage surgical risk. Operator experience, symptomatic
tatus, and hypertension were found to be independent
redictors of adverse events. If the remarkably low event
ates in this study are reproduced, it may elevate proximal
rotection to a leading role in carotid stenting.
ES for below-the-knee critical limb ischemia. The
ARADISE (Preventing Amputations Using Drug Eluting
tents) trial (65), a prospective registry of 106 patients (118
imbs), investigated the efficacy and safety of DES (n 
28) to prevent amputations in patients with below-the-
nee critical limb ischemia. There were no procedural
eaths, and 96% of patients were discharged within 24 h.
he 3-year cumulative incidence of amputation was 6 
%, survival was 71 5%, and amputation-free survival was
8  5%. Rutherford category, age, creatinine level, and
ialysis (p  0.001 to 0.04) were predictors of death but not
mputation. Target limb revascularization occurred in 15%
f patients, and repeat angiography in 35% of patients
evealed a binary restenosis in 12%. Limb salvage and
urvival rates in patients treated with DES exceed those of
istoric controls. The authors conclude that treating below-
he-knee critical limb ischemia with DES is an effective and
afe means of preventing major amputation and relieving
ymptoms.
ate neointimal effects of BMS. Takano et al. (66)
xamined the neointimal characteristics of BMS by optical
oherence tomography during the early (6 months, n 
0) and late phases (5 years, n  21) after implantation.
ormal neointima proliferated homogeneously, and lipid-
aden intima was not observed in the early phase. In the late
hase, lipid-laden intima, intimal disruption, and thrombus
requently were found in comparison with the early phase.
he appearance of intraintima neovascularization was more
revalent in the late phase than in the early phase (62% vs.
%, respectively; p 0.01) and in segments with lipid-laden
ntima than in nonlipidic segments (79% vs. 29%, respec-
ively; p  0.026). These remarkable optical coherence
omography finding suggest that neointima within the BMS
ften transforms into lipid-laden tissue and may explain
ome of the late adverse events noted with BMS. cntravascular Ultrasound Predictors
f Plaque Morphology and Progression
ubo et al. (67) used virtual histology (VH) intravascular
ltrasound (IVUS) to investigate the natural history of
oronary lesion morphology by performing baseline and
2-month follow-up studies in 216 nonculprit lesions
plaque burden 40%) in 99 patients. Lesions were classi-
ed into pathological intimal thickening, thin-capped fibro-
theroma (TCFA), thick-capped fibroatheroma (ThCFA),
brotic plaque, and fibrocalcific plaque. At baseline, 20
esions were VH TCFAs; during follow-up, 15 (75%) VH
CFAs “healed,” 13 became ThCFAs, 2 became fibrotic
laque, and 5 (25%) VH TCFAs remained unchanged.
ompared with VH TCFAs that healed, VH TCFAs that
id not were located more proximally and had larger lumen,
essel, and plaque areas but not baseline VH IVUS plaque
omposition. Conversely, 12 new VH TCFAs developed; 6
ere pathological intimal thickenings and 6 were ThCFAs
t baseline. In addition, plaque area at minimum lumen sites
ncreased significantly in all but fibrous or fibrocalcific
laque. This longitudinal study suggests novel insights into
laque progression, and by inference imaging of stable and
ctive plaques, that will help guide future imaging and
herapeutic trials using such techniques.
Bayturan et al. (68) evaluated 3,437 patients with CAD
ndergoing serial IVUS examination in 7 clinical trials.
atients who achieved an on-treatment LDL cholesterol
evel of 70 mg/dl (n  951) were stratified as progressors
n  200) or nonprogressors. Despite achieving LDL
holesterol 70 mg/dl, 20% of patients continued to
rogress. Progressors demonstrated higher baseline levels of
lucose, triglycerides, and a smaller decrease of apo-B at
ollow-up. Multivariable analysis revealed that indepen-
ently associated risk factors of progression included base-
ine percent atheroma volume, diabetes mellitus, increase in
ystolic blood pressure, less increase in HDL cholesterol,
nd a smaller decrease in apo-B levels, but not changes in
RP or LDL cholesterol. This study highlights the impor-
ance of residual risk factors, particularly LDL particle
oncentration, in the progression of atherosclerosis in pa-
ients who achieve very low LDL cholesterol levels.
In another IVUS study, Nicholls et al. (69) examined the
elationship between IVUS measures and CV outcomes, by
efining the relationship between baseline and change in
ercent atheroma volume (PAV) and total atheroma volume
nd total with MACE in 4,137 patients and 6 clinical trials.
reater baseline PAV was observed in patients with MI,
oronary revascularization, or MACE. Importantly, each
tandard deviation increase in PAV with associated with a
.32-fold greater likelihood of experiencing MACE. Thus,
his study demonstrated a relationship between the burden
nd progression of coronary atherosclerosis as defined by
VUS and the occurrence of MACE. The investigators
ontended that their data support the use of IVUS as a
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otic therapies.
xidation-Specific Biomarkers and Lipoprotein(a)
he relationship of a panel of oxidative biomarkers and
ipoprotein(a) to CAD risk was determined in the prospec-
ive case-control study nested in the EPIC (European
rospective Investigation of Cancer)-Norfolk cohort of 45-
o 79-year-old apparently healthy men and women followed
p for 6 years (70). After adjusting for conventional risk
actors, the highest tertiles of oxidized phospholipids on
po-B-100 particles and lipoprotein(a) were associated with
significantly higher risk of CAD events (OR: 1.67 and
.64, respectively; p  0.001) compared with the lowest
ertiles, which was significantly potentiated (approximately
oubled) by the highest tertiles of secretory phospholipase
2 activity and mass but less so for myeloperoxidase and
ipoprotein-associated phospholipase A2 activity. After tak-
ng into account the Framingham Risk Score, c-index values
rogressively increased when oxidative biomarkers were
dded to the model. This EPIC-Norfolk study links patho-
hysiologically related oxidation-specific biomarkers and
ipoprotein(a) with CAD events and suggests that they
rovide cumulative predictive value when added to tradi-
ional CV risk factors.
A systematic review of 40 studies involving 58,000
articipants measured apo(a) isoforms and determined their
isk of vascular disease (71). Thirty-six studies used broadly
omparable phenotyping and analytic methods to assess
po(a) isoform size. These studies yielded a combined
elative risk for CHD of 2.08 for subjects with smaller
ersus larger apo(a) isoforms. There was substantial heter-
geneity among these studies (I2  85%, 80% to 89%),
hich was mainly explained by differences in the laboratory
ethods and analytic approaches used. In the 6 studies of
schemic stroke that used comparable phenotypic methods,
he combined relative risk was 2.14. Thus, persons with
maller apo(a) isoforms have an approximately 2-fold higher
isk of CHD or ischemic stroke than do those with larger
roteins.
lcohol Septal Ablation
lcohol septal ablation represents an interventional therapy
or hypertrophic cardiomyopathy. Agarwal et al. (72) per-
ormed a meta-analysis of 12 studies in an attempt to
ompare the efficacy of alcohol ablation versus surgical
yectomy. No significant difference between alcohol abla-
ion or surgical myectomy could be found in either short-
erm or long-term mortality or post-interventional func-
ional status, functional class, ventricular arrhythmias,
einterventions, or mitral regurgitation. However, septal
lcohol ablation did increase the risk of right bundle branch
lock, the need for a permanent pacemaker, and was vssociated with a significantly higher residual gradient in the
eft ventricular (LV) outflow track. In the absence of a
andomized prospective clinical trial comparing these 2
herapeutic approaches, this meta-analysis suggests that
eptal alcohol ablation yields similar results to those for the
reatment of hypertrophic obstructive cardiomyopathy.
eart Rhythm Disorders
echanisms of atrial fibrillation. Recent studies have cast
oubt on the hypothesis that paroxysmal atrial fibrillation
AF) progresses to persistent AF (73). De Vos et al. (73)
tudied the clinical correlates of patients in whom paroxys-
al AF did and did not progress to persistent AF, to define
scoring system for progression. In 1,219 paroxysmal AF
articipants, AF progressed at 1 year in 15%. On multivar-
ate analysis, HATCH (an acronym for heart failure, age,
revious transient ischemic attack or stroke, chronic ob-
tructive pulmonary disease [COPD], and hypertension)
ndependently predicted AF progression. The researchers
reated a HATCH score for AF progression: half of
atients with HATCH score  5 but only 6% of patients
ith score  0 progressed to persistent AF; HATCH thus
ad prognostic value. An accompanying editorial (74)
greed that the HATCH score may identify patients likely
o progress to persistent AF and, if validated, may provide
mportant bedside prognostic information.
Several studies have associated single nucleotide polymor-
hisms (SNPs) with AF, particularly those on chromosomes
q25 and 16q22 (75,76). However, applying these data to
linical management has been unclear. A thought-
rovoking study in JACC by Husser et al. (77) showed that
NPs on chromosome 4q25 may identify patients with AF
ecurrence after ablation. In 195 AF patients undergoing
blation for drug, the authors studied SNPs rs2200733 and
s10033464 on chromosome 4q25 and prospectively as-
essed for AF recurrence per guidelines. Recurrent AF
ccurred in 37% within 7 days (“early”), and 21% at 3 to 6
onths (“late”), and was not predicted by clinical charac-
eristics. However, the presence of any variant allele (of
dentified SNPs) was strongly associated with early recur-
ence (OR: 1.994) and late recurrence (OR: 4.182). While
alling for additional studies, an accompanying editorial
76) agreed that polymorphisms on chromosome 4q25 may
odulate risk for AF recurrence after catheter ablation,
ointing to a potential clinical role in risk stratification.
Ablation for persistent AF may involve extensive ablation
o isolate the pulmonary veins (PV), ablate the left atrial
oof, and interrupt circuits in other locations. However, the
echanistic rationale for each of these lesion sets is unclear.
ishida et al. (78) mapped canine AF circuits, then assessed
he impact of the PV isolation and roof ablation of an
xtensive AF ablation procedure. The PV isolation failed to
erminate AF, but did decrease AF vulnerability to single
xtrastimuli by increasing effective refractory periods. Con-
ersely, left atrial roof ablation terminated AF in 67% of
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Highlights From JACC 2010 January 25, 2011:480–514ogs and reduced AF duration without affecting AF vul-
erability. The authors conclude that PV isolation and left
trial roof ablations have beneficial but limited actions in
his canine model, further emphasizing the need to system-
tically study individual step-wise components to refine AF
blation procedures.
The search for more effective pharmacological therapy for
F continues. Burashnikov et al. (79) used ex vivo canine
erfused canine atrial, PV, and ventricular preparations to
tudy the independent and concomitant effects of ranolazine
nd dronedarone on AF vulnerability (79). The authors
ound that low concentrations of ranolazine and dronedar-
ne weakly suppressed AF, yet their combination potently
epressed atrial-selective sodium channel activity and sup-
ressed AF. This study supports future clinical trials.
inus nodal function. An elegant report by Fedorov et al.
80) used optical mapping of atria from human explanted
earts to define the functional sinoatrial node (SAN).
ptical signals from the SAN region showed diastolic
epolarization and multiple upstroke components, corre-
ponding to the separate excitations of SAN and atrial
ayers. Excitation originated in the middle of the SAN, then
pread slowly and anisotropically from it, to excite atrial
yocardium via superior, middle, and/or inferior sinoatrial
athways. Notably, the oval SAN was functionally insulated
rom the atrium by connective tissue, fat, and coronary arteries,
xcept for these pathways. The investigators conclude that
hese are the first data to show the location of the leading SAN
acemaker site, the pattern of excitation within the human
AN, and the conduction pathways into the right atrium.
hese findings have clinical significance in understanding the
athophysiology of atrial tachyarrhythmias.
yncope. A definitive diagnosis for syncope is often diffi-
ult to achieve. The ROSE (Risk Stratification of Syncope
n the Emergency Department) study, published by Reed et
l. (81), prospectively developed a clinical decision rule to
redict serious 1-month outcome and all-cause mortality
mong patients presenting to the emergency department
ith syncope. From this single-center, prospective, obser-
ational study was derived the ROSE rule and subsequently
alidated it in 550 patients each. Independent predictors of
erious 1-month outcome or all-cause death that occurred in
.3% patients were brain natriuretic peptide (BNP) concen-
ration300 pg/ml, positive fecal occult blood, hemoglobin
9 g/dl, oxygen saturation 94%, and Q-wave on electro-
ardiogram; and were similar in the validation cohort. The
OSE rule had a sensitivity and specificity of 87.2% and
5.5%, respectively, and a negative predictive value of
8.5%. Elevated BNP alone was a major predictor of serious
V outcomes (8 of 9 deaths, 89%). Thus, the ROSE rule
and particularly its BNP component) has excellent sensi-
ivity and negative predictive value for identifying high-risk
atients with syncope.
udden cardiac arrest and implantable cardioverter-
efibrillator therapy. The automated external defibrillator
AED) has the potential to reduce mortality from sudden cardiac arrest (SCA) in high-risk public places. Weisfeldt et
l. (82) reported the relationship of AED application
before emergency medical services) to survival to hospital
ischarge in a cohort with nontraumatic out-of-hospital
CA. From the Resuscitation Outcome Consortium, 4,403
ut-of-hospital received bystander cardiopulmonary resus-
itations (CPRs) without AED use, and 289 CPRs with
ED were applied by health care workers (32%), lay
olunteers (35%), police (26%), or others (7%). Survival was
% (382 of 4,403) with bystander CPR without AED, 24%
69 of 289) with AED use, and 38% (64 of 170) with AED
hock delivered. In multivariate analyses, AED use was
ssociated with greater likelihood of survival (OR: 1.75; p
.002). Extrapolating the observed survival benefit from to
he entire U.S. and Canadian population (330 million),
ED application by bystanders might save 474 lives a year.
Kanoupakis et al. (83) tested the hypothesis that serum
arkers of collagen turnover, reflecting turnover in ventric-
lar myocardium, may contribute to substrates for ventric-
lar arrhythmias. In 70 patients with nonischemic cardio-
yopathy, and an implantable cardioverter-defibrillator
ICD) for primary prevention, the authors measured serum
-terminal propeptide of collagen type-I, C-terminal te-
opeptide of collagen type-I, matrix metalloproteinase
MMP)-1, and tissue inhibitor of MMP-1. The authors
ound appropriate ICD therapies in 14 of 70 patients during
-year follow-up. Pre-implantation serum levels of C-terminal
elopeptide of collagen type-I were significantly baseline
MP-1 and tissue inhibitor of MMP-1 higher in patients
ith ICD therapy than without ICD therapy. The authors
oncluded that serum markers of collagen turnover, possibly
eflecting altered extracellular matrix that influences the ar-
hythmogenic substrate in nonischemic cardiomyopathy, may
redict arrhythmic events in ICD recipients.
Data continue to accrue on ICD risks. Lee et al. (84)
eported complications from ICD insertion in a multicenter
egistry of 18 centers. The authors noted 45-day major
omplications in 4.1% of procedures. Implantation of a
ardiac resynchronization defibrillator or dual-chamber de-
ice was associated with an increased risk of major compli-
ations, which were higher in women and when end-systolic
imension exceeded 45 mm. Major complications (exclud-
ng death) early after ICD insertion were associated with
ncreased risk of death. Direct ICD-related complications
ere associated with higher risk for early death (HR: 24.89),
hereas indirect complications increased the risk for near-
erm death (HR: 12.35). The authors concluded that major
omplications occurred in 4.1% of de novo ICD inserts,
ere strongly associated with device type, and were associ-
ted with increased risk of mortality.
Chung et al. (85) reported on compliance with, and
fficacy of, the wearable cardioverter-defibrillator (WCD)
or prevention of sudden death in patients whose risk for
entricular arrhythmias is being ascertained, or who tempo-
arily cannot receive an ICD because of infection or other
omorbidity. In 6,569 WCD recipients, daily use was90%
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January 25, 2011:480–514 Highlights From JACC 2010f the day in 52% of patients, with 15% of patients
iscontinuing use because of discomfort or adverse reac-
ions. Eighty sustained ventricular tachycardia/ventricular
brillation (VT/VF) events were noted in 59 patients
1.7%). First-shock success was 100% for unconscious
T/VF and 99% for all events, and resulted in a 89.5%
urvival from VT/VF events. During WCD use, 3,541 of
,569 patients (99.2%) survived overall. Using the Social
ecurity Death Index, long-term mortality was not signifi-
antly different from first ICD implant patients. As edito-
ialized by Verdino (86), wear time with the WCD was
atisfactory and the WCD provided a survival from sudden
eath comparable to that with ICD, although asystole was
ot addressed by the WCD.
blation of ventricular tachycardia. Nakahara et al. (87)
eport a mapping study for substrates for VT, in cardiomy-
pathy patients with a particular focus on low voltage late
otentials (LP) as targets for catheter ablation. In 33
ardiomyopathy patients referred for VT ablation, they
apped the endocardium (n 33) and epicardium (n 19)
o identify LP, defined as electrograms1.5 mV with onset
fter the QRS interval, and very late potentials (vLP),
efined as onset 100 ms after the QRS. Sampling 564 
49 endocardial points and 726  483 epicardial points in
he left ventricle per patient, the authors found low voltage
reas in the endocardium and epicardium. Patients with
schemic myopathy had a larger endocardial low voltage area
nd frequencies of vLP than nonischemic myopathy
NICM) patients. Notably, LP-targeted ablation was effec-
ive in ischemic myopathy patients (82% nonrecurrence at
2 months) but less in NICM patients (50% at 15 months).
he authors concluded that the cause of signal types often
argeted for VT ablation (LP and vLP) may differ between
schemic myopathy and NICM, and that approaches other
han LP ablation, and pace-mapping may be required in
ICM patients.
As suggested by the above study, epicardial mapping is
ncreasingly used during VT ablation. Sacher et al. (88)
xamined the necessity and safety for this approach from
T ablation at 3 referral centers. Of 913 VT ablations, 156
rocedures (17%) involved epicardial mapping and/or abla-
ion, performed in 134 patients mostly after a previous VT
blation. Notably, 51 patients had ischemic cardiomyopa-
hy, 39 had nonischemic cardiomyopathy, 14 had arrhyth-
ogenic right ventricular cardiomyopathy, and 30 had other
ypes of cardiomyopathy. Overall, 136 procedures were
erformed by percutaneous subxiphoid puncture, 14 by a
urgical subxiphoid approach, and 6 during open-heart
urgery. Epicardial ablation was performed in 121 of 156
rocedures (78%) and was subsequently delivered endocar-
ially in 21%. Twenty patients subsequently required repeat
rocedures, and the epicardium could be reaccessed in all
ut 1 patient. The authors observed a total of 8 (5%) major
omplications acutely, including 7 epicardial bleeding events
nd 1 coronary stenosis. After 23  21 months of follow-
p, 3 delayed complications included 1 major pericardial enflammatory reaction, 1 delayed tamponade, and 1 coro-
ary occlusion after 2 weeks. Constrictive pericarditis or
hrenic nerve injuries were not observed. An accompanying
ditorial (89) places these data in the context of prior
tudies, in which epicardial ablation was also more likely to
e required in patients with nonischemic cardiomyopathy or
rrhythmogenic right ventricular cardiomyopathy, and out-
ines future trends in VT ablation.
ong QT syndrome (LQTS). Several studies addressed
he link between the LQTS and life-threatening ventricular
rrhythmias. Viskin et al. (90) examined the utility of a
imple bedside test to improve diagnosis: that is whether
hort-lived sinus tachycardia from the orthostatic response
o standing exposes abnormal QT prolongation in patients
ith LQTS. The authors examined 68 patients with LQTS
nd 82 control subjects. In response to brisk standing,
atients and control subjects responded with similar heart
ate acceleration of 28  10 beats/min (p  NS). However,
he QT interval shortened in controls by 21 ms and
engthened in LQTS patients by 4 ms (p  0.001), so that
orrected QT interval increased by 50  30 ms in controls
nd 89 47 ms in LQTS patients (p 0.001). The authors
oncluded that evaluating the QT-interval response to the
risk tachycardia induced by standing may aid in the
iagnosis of LQTS.
Although syncope is highly predictive for future fatal
rrhythmias in LQTS, few data exist to stratify such risk.
ons et al. (91) studied 1,059 LQTS patients from the
nternational LQT registry with corrected QT interval
450 ms and syncope as a first symptom. The investigators
ound that the lowest risk for a “severe arrhythmic event”
ccurred with only 1 syncopal episode before beta-blocker
herapy. In contrast, patients with syncope after starting
eta-blocker therapy had a 3.6-fold increase in the risk of
evere arrhythmic events compared to patients not treated
ith beta-blockers. The risk of syncope during beta-blocker
herapy was high during childhood in both sexes but higher
n women (HR: 2.3, p  0.001). The authors concluded
hat patients with LQTS and syncope during beta-blocker
herapy are at high risk of life-threatening events, and
hould be considered for ICDs.
ardiac resynchronization therapy (CRT). There is in-
reasing evidence that patient-tailored lead location may
mprove the hemodynamics of CRT (92). Spragg et al. (93)
tudied the impact of endocardial LV pacing site on the
echanical response to CRT in patients with ICM. The
uthors studied peak rate of LV pressure increase (dP/dtmax)
t baseline, during VDD pacing at the right ventricular
pex, and during biventricular pacing from the right ven-
ricular apex and 51 LV endocardial sites in 11 patients with
CM. They used electroanatomic mapping to create color-
oded maps of dP/dtmax within the ventricle. The authors
ound that endocardial biventricular pacing improved dP/
tmax over right ventricular apical pacing. In 7 patients with
reexisting CRT leads, LV dP/dtmax was equivalent for
ndocardial and epicardial pacing, but dP/dtmax at the best
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mplanted CRT. An average of 2 optimal endocardial sites
yielding 85% of maximum dP/dtmax) were identified for
ach patient, located at the extreme basal lateral wall (8 of
1 patients) and elsewhere (9 of 11 patients). Standard
id-LV free wall pacing yielded suboptimal LV function in
3% of patients. Optimal pacing sites were typically located
n LV territories remote from the infarct zone. An accom-
anying editorial emphasized that CRT delivered at the best
V endocardial sites for any given patient was more effective
han by pre-implanted coronary sinus leads, confirming
esults of a paper published in the Journal in 2010 regarding
atients with nonischemic cardiomyopathy, by Derval and
ais (94).
efibrillator electrograms. Multiple configurations of
entricular tachycardias are typically inducible in patients
n whom ICDs have been implanted. Yoshida et al. (95)
et out to determine whether an electrogram recorded on
he ICD could in fact differentiate the actual clinical
rrhythmias occurring from others inducible at the time
f testing (95). They found that electrograms stored on
he ICD accurately identified clinical VTs from 98% of
ther VTs. By visual inspection of the ICD electrograms,
6% of clinical VTs were accurately differentiated from
reviously undocumented VTs. In addition, pace map-
ing based on ICD electrograms were found to be useful
or identifying a VT exit site. This study validates the
sefulness of defibrillator electrograms for recognizing
linical VTs. In an accompanying editorial, Almendral
nd Marchlinski (96) indicate that this work suggests
hat in the management of VT with catheterization
blation procedures, ICD electrograms could become the
ew “standard” link between spontaneous phenomena
nd induced arrhythmias.
Singh et al. (97) reviewed the clinical trials reported to
ate on the new antiarrhythmic drug developed for the
reatment of AF. The authors summarized the DAFNE
Dronedarone Atrial Fibrillation Study after Electrical Car-
ioversion), EURIDIS (European Trial in Atrial Fibrilla-
ion or Flutter Patients Receiving Dronedarone for the
aintenance of Sinus Rhythm), ADONIS (American-
ustralian-African Trial with Dronedarone in Patients with
trial Fibrillation or Atrial Flutter for the Maintenance of
inus Rhythm), and ATHENA (A Trial with Dronedarone
o Prevent Hospitalization or Death in Patients with Atrial
ibrillation) trials and noted a modest antiarrhythmic drug
fficacy of dronedarone compared with other antiarrhythmic
rugs and placebo. Patients administered dronedarone had a
ecurrence rate of AF or atrial flutter of 43% compared with
4% in patients on placebo (p  0.0001), comparable to
uinidine. In the DIONYSIS (Efficacy and Safety of
ronedarone versus Amiodarone for the Maintenance of
inus Rhythm in Patients with Atrial Fibrillation) study,
he composite endpoint of AF recurrence or premature drug
iscontinuation in patients on drug for at least 6 months was
eached by 74% of patients on dronedarone versus 55% on rmiodarone. Dronedarone was effective in reducing ventric-
lar rate on AF compared with placebo. Dronedarone was
ound to increase mortality in the ANDROMEDA (Euro-
ean Trial of Dronedarone in Moderate to Severe Conges-
ive Heart Failure) trial, in patients with moderate to severe
HF. This increased mortality rate appeared to be due
argely to worsening of heart failure, predominately in those
atients with recently decompensated heart failure. In con-
rast, in the ATHENA trial, in patients with compensated
eart failure, there was a 24% reduction in combined risk of
V hospitalization and all-cause mortality compared with
lacebo at 21 months follow-up. The Food and Drug
dministration approved dronedarone for treatment of
F/atrial flutter largely on the basis of the results of the
THENA trial. The researchers note, however, that in a
ooled analysis of these 6 studies, in a total of 6,771
atients, dronedarone treatment was not significantly dif-
erent with respect to placebo in the incidence of all-cause
ortality of CV hospitalization. With respect to side effects,
ronedarone was noted in these studies to cause a slight
ncrease in creatinine due to inhibition of renal tubular
ecretion. The main clinical side effects were diarrhea,
ausea, and vomiting. Thus, the authors concluded that
ronedarone was moderately effective in the treatment of
F/atrial flutter, it may reduce CV hospitalization and
ll-cause mortality, it had less toxicity than amiodarone, it
hould not be used in patients with decompensated heart
ailure, and it is most likely a second- or third-line agent.
he researchers also noted that its high cost (as much as $9
er day) makes it uncertain if it will be cost effective
ompared with generic amiodarone.
Fein et al. (98), provide an important perspective on the
se of CRT outside of the guidelines from the National
ardiovascular Data Registry (NCDR) ICD registry. More
han 75% of hospitals nationally submit data to this registry.
he authors examined a cohort of 45,392 CRT-defibrillator
mplants for primary prevention of sudden death. They
efined “off-label” implants, however, as those in patients
ith an ejection fraction (EF) 35%, New York Heart
ssociation (NYHA) functional class III, or a QRS
uration 120 ms. The investigators found that 23.7% of
evices were implanted without meeting all 3 implant
riteria, most often due to NYHA functional class III or
RS duration 120 ms. Physician training and insurance
ayer were weakly associated with the likelihood of off-label
se. Thus, nearly 25% of patients undergoing CRT therapy
eported to the NCDR registry during the study time frame
id not meet guideline-based indications for device implan-
ation. While the investigators refrain from equating off-
abel use of CRT devices with inappropriate care, they do
uggest that these apparently aberrant practices require
areful scrutiny.
The effects of chronic stretch due to mitral valve stenosis
nd its reversal after mitral commissurotomy (MC) on the
lectrophysiological properties of the human atria were
eported this year (99). Because atrial stretch due to mitral
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January 25, 2011:480–514 Highlights From JACC 2010tenosis is a known common cause of AF, studying the atrial
lectrophysiology before and after the relief of this stretch
ould appear to be good method to correlate electrophysi-
logic characteristics with a substrate known to predispose
o AF. The researchers evaluated 21 patients with mitral
tenosis undergoing MC, before and after intervention.
hey observed that, immediately after MC, there was
ignificant increase in mitral valve area, with significant
ecrease in left atrial and pulmonary artery pressures and left
trial volume. That was associated with reduction in P-wave
uration, an increase in conduction velocity and voltage in
oth the left atrium and right atrium, but no change in
ffective refractory period (ERP). Late after MC, mitral
alve area remained improved, but there was an even further
ecrease in P-wave duration, associated with further in-
reases in conduction velocity and voltage in the right
trium, and ERP decreased. They concluded that the atrial
lectrophysiologic and electroanatomic abnormalities that
esult from chronic stretch due to mitral stenosis do signif-
cantly reverse after MC, and that the substrate predisposing
o atrial arrhythmias may therefore be reversed as well. The
uthors did not assess inducibility of AF or report on the
ncidence of AF late after MC. These observations suggest
hat abnormalities in conduction velocity and voltage may
e more important in generating the substrate predisposing
o AF than shortening of ERP, which, interestingly, was
bserved to shorten even further late after MC in these
atients.
Tedrow et al. (100) evaluated the effects of BMI on the
isk of new AF during nearly 13 years of follow-up in the
omen’s Health Study, to assess the relationship between
hanges in BMI and incident AF. They note that both
besity and AF are increasing public health problems, but
he role of obesity in AF is uncertain. Over 12.9 1.9 years
f follow-up, 834 AF events were confirmed after chart
eview. The researchers determined that BMI was linearly
ssociated with AF risk, with a 4.7% (p  0.0001) increase
n risk with each kg/m2. When long-term measures of BMI
ere utilized to estimate dynamic risk, overweight (HR:
.22, 95% CI: 1.02 to 1.45, p  0.03) and obesity (HR:
.65, 95% CI: 1.36 to 2.00, p  0.0001) were associated
ith adjusted short-term elevations in AF risk. Participants
ecoming obese during the first 60 months had a 41%
djusted increase in risk of developing AF (p  0.02)
ompared with those maintaining BMI 30 kg/m2. The
orrelation between BMI and AF risk appeared strongest in
omen 60 years of age and younger, whereas this correla-
ion was not observed in women older than 60 years at
aseline. From their observations, the authors concluded
hat in this population of initially healthy, middle-aged,
emale healthcare professionals, elevated BMI was associ-
ted with both short- and long-term elevations in AF risk,
ccounting for a large proportion of incident AF indepen-
ent of traditional risk factors. bongenital Heart Disease
tarting with therapy from before birth, a paper by Jaeggi et
l. (101) evaluated the level of maternal anti-Ro/SSA
ntibodies as prognostic markers for development of cardiac
eonatal lupus, and especially complete atrioventricular
AV) block (101). Transplacental anti-inflammatory treat-
ent with maternal steroids was indicated if complete AV
lock reduced contractility, with intravenous immunoglob-
lin given to the mother (70 g every 2 to 3 weeks) and to the
ewborn in a single dose (2 g/kg). Five percent of the 359
rospectively screened and treated pregnancies resulted in
omplete AV block. Anticipated is a large study with
mmunoglobulin treatment begun earlier, and in situations
ith high levels of maternal antibodies rather than just a
resence with associated fetal tissue injury.
A study by Avis et al. (102) looks at the safety and efficacy
f rosuvastatin therapy for children with familial hypercholes-
erolemia. Twenty milligrams per day reduced LDL choles-
erol by 50%; but only 40% of the patients attained a consistent
arget of 110 mg/dl LDL cholesterol. Four patients had
ery high creatine kinase levels during the administration of
osuvastatin (2 each with 10 mg and 20 mg, respectively).
osuvastatin was, in general, well tolerated.
A study by Kantor et al. (103) highlighted the impact of
hanging medical therapy on transplantation-free survival in
ediatric patients with dilated cardiomyopathy. This single-
enter study included children with dilated cardiomyopathy,
arying in severity and age at presentation. Lower EF at
resentation and the absence of acute myocarditis were
ssociated with poor outcome. There was only a transient
urvival associated with combined use of angiotensin-
onverting enzyme inhibitors and beta-blockers, and no
bvious sustained improvement accompanying digoxin-
ased therapy. The investigators concluded that the etiology
ather than the choice of therapy is most related to outcome,
ith cardiac transplantation remaining the most viable in
he long term.
A study by Moulik et al. (104) sought to evaluate the
revalence and outcome of viral endomyocarditis infection
fter transplantation and the effect of treatment with hyper
mmune intravenous immunoglobulin. Ninety-four patients
ith a mean age at transplantation of 6.5 years had
ongenital heart disease (36%), dilated cardiomyopathy
35%), restrictive cardiomyopathy (14%), and retransplan-
ation (13%). The investigators conclude that viral infection
f the endomyocardium is common after pediatric heart
ransplant, and is an independent risk factor for graft loss.
utcomes suggest that adverse outcome may be delayed by
sing intravenous immunoglobulin, and hence polymerase
hain reaction screening, surveillance, and biopsies for
ardiotropic viruses is indicated. The viral genome itself was
n independent risk factor for graft loss, and, therefore, the
uthors suggest that evaluation of other methods (interferon
eta therapy, cellular immune therapy) may need to be
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ndomyocarditis is poor.
A paper by Apitz et al. (105) related to nonstructural
ongenital heart disease describes treatment of pulmonary
ypertension with oral sildenafil. They studied 36 patients
ith a mean age 7.5 years, 8 of whom had idiopathic
ulmonary hypertension, the remainder of whom had pul-
onary hypertension associated with congenital heart dis-
ase. Hemodynamics and serum cyclic-guanosine mono-
hosphate were monitored at baseline and after inhaled
itric oxide, and the same measurements and sildenafil
evels were measured 30 min after sildenafil. The vasodilat-
ng ability of sildenafil was lower than that of inhaled nitric
xide—2.8% versus 11.6% reduction of pulmonary vascular
esistance indexed for body surface area. For patients with
etectable sildenafil levels, the vasodilating capability was
ot statistically different from inhaled nitric oxide. Higher
ildenafil levels were found in the patients with idiopathic
ulmonary hypertension, whereas no responses were fre-
uently seen in pulmonary hypertension associated with
ongenital heart disease. Although sildenafil may be effec-
ive in some patients, suboptimal absorption of sildenafil
ccurs in almost half of the children undergoing acute
emodynamic testing.
tructural forms of congenital heart disease, therapy, and
utcomes. Harrild et al. (106) examined exercise capacity,
entricular volumes, and function in 41 patients after
alloon dilation for significant pulmonary stenosis, either
ative or residual. Most patients had a pulmonary regurgi-
ation (PR) regurgitant fraction of 10%; 34% of the
atients had PR 15%, and 17% had PR 30%. Higher
egurgitant fraction was found by magnetic resonance im-
ging (MRI) in patients 1 year of age at time of valvulo-
lasty and with balloon to artery ratios 1.4. Only 2
atients had severe PR, regurgitant fraction40%. Exercise
apacity in patients with PR regurgitant fraction of 15%
as significantly higher by VO2.
The conclusions were that mild PR and right ventricular
RV) dilation were common in the long-term follow-up of
alloon dilation. A PR 15% was associated with lower
O2 and more often RV dilation and impaired exercise
unction in the aftermath of balloon valvuloplasty for
ulmonary stenosis. The accompanying editorial, by Latson
107), points out that isolated pulmonary stenosis patients
ave greater preserved RV function and less RV dilation
han patients who had surgery for tetralogy of Fallot.
esidual after Fontan operation for complex single ventricle
nd other disorders. Rathod et al. (108) studied 90 patients,
8% having significant positive late gadolinium enhance-
ent, in whom the dominant ventricle had a lower EF
45%), increased mean end-diastolic volume, and increased
entricular mass. In the patients with significant late gado-
inium enhancement, the median percent ranged from 3.3
o 9.8 of the myocardium. Most (64%) was observed in the
all of the primary ventricle, 36% in the free wall of theecondary ventricle, and 16% in the defective septum. tPatients with late gadolinium were much more likely
62% vs. 28%) to have regional wall motion abnormalities
nd associated dyskinesis. Distribution of gadolinium varied
rom completely subendocardial to patchy. In the exercise
ests performed within 1 year of cardiac magnetic resonance
maging, the late gadolinium results were not associated
ith changes in exercise capacity. Patients with more
adolinium-enhancing area did have a higher incidence of
onsustained VT.
A multicenter study investigated the presence and clinical
ssociations of arrhythmias in a Fontan cohort—7 centers
nd 520 patients total, from 6 to 18 years after Fontan
109). Supraventricular tachycardia was present in 9.6% and
ntra-atrial reentry tachycardia in 7.3%—lower in this co-
ort than previously reported. Lower functional status and
orticopulmonary connection and a paced rhythm were
etermined to be independently associated with intra-atrial
e-entrant tachycardia (IART) after Fontan.
The IART increased with the age of patients and length
ince the time of Fontan and later childhood. Presence of
ART was slightly higher in L-looping abnormalities.
either the degree of AV valve regurgitation nor systemic
entricular EF was associated with IART, but post-protein
osing enteropathy occurred in 7.9% of patients with IART
ompared with 2.9% of patients without IART. The pres-
nce of IART was lower than in previous reports, and
ndependent associations of IART development include a
aced rhythm, lower functional status, and an atrial-
ulmonary connection.
An editorial comment by Van Hare (110) concludes that
he fact that they are unable to avoid these serious atrial
rrhythmias despite evolution of the procedure means that
e may have to consider what is done at the time of Fontan
ompletion. In his editorial, Van Hare (110) referred to a
aper whose investigators strategically placed atrial incisions
o avoid recurrence of flutter, and that some of the mapping
nd ablation in electrophysiology therapies should have
rovided information to help us understand the elements—
he substrate for atrial arrhythmia—and to help develop and
esign more effective surgical techniques to avoid it in the
rst place.
A multicenter study for the Alliance for Adult Research
n Congenital Cardiology (111) examined a not-surprising
et of difficulties in the aftermath of Fontan—the status of
ower extremities systemic venous health, the so-called
ALF (Congenital Heart Disease in Adults Lower Ex-
remity Systemic Venous Health in Fontan Patients) study.
his study included 159 adults with Fontan physiology
ompared with age-matched controls. Significant venous
bnormalities occurred in almost double the number (mean
0%) of the Fontan patients compared with age-matched
ealthy controls (mean 32%). Comorbidities included
hromboembolism, heart failure, and interventions to im-
rove hemodynamic conditions. A thoughtful editorial by
arelli (112) points out that Fontan patients have capturedhe imaginations of surgeons and cardiologists and that a
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amics and ventricular function as well as ventricular type
nd morphology might be of further help.
Tobler et al. (113) reported 65 adults followed up in the
oronto Congenital Cardiac Centre for Adults, among 132
nfants surviving operation for arterial switch before 1991.
f these 65 adults, 11 had at least 1 significant cardiac
esion, including ventricular dysfunction, valve dysfunction,
r arrhythmia. Residual lesions were more common in
atients who had cardiac reinterventions in childhood; 8
ad arrhythmias requiring reoperation or pacemaker im-
lantation. Intervention for aortic valve and aortic root was
ot observed, and exercise capacity was reduced in 82%.
Adults with surgical evaluation before arterial switch were
ore likely to have significant residua than were those who
ad primary arterial switch. Although further follow-up is
eeded, neoaortic valve regurgitation and aortic root dila-
ion was not prominent in this group. Cardiac reinterven-
ions after age 18 years mainly occurred for relief of RV
utflow tract obstruction and pulmonary valve stenosis. This
tudy highlights overall good outcomes in this early cohort,
ut the subgroups who needed further interventions in
hildhood are at higher risk for ventricular dysfunction,
alve dysfunction, and arrhythmias.
The natural history of adult patients with bicuspid aortic
isease—viewed previously as a relatively simple abnormality—
as now come into question (114). A timely review points
ut that eventual abnormal shear stress leads to valve
alcification and raises the risk of continuing aortic dilation,
specially in patients 30 years of age with moderate to
evere aortic stenosis or incompetence. The prevalence of
ortic sinus dilation was 28% in a paper from Toronto,
escribing adults with a mean age of 35  16 years. Aortic
issection occurs in 0.1% for patient-year follow-up. Be-
ause there is a risk of further root dilation, many surgeons
onsider reinforcing or replacing the ascending aorta at the
op of valve surgery. Pregnancy also seems to accelerate the
eed for surgery in post-partum women with moderate or
evere aortic stenosis. Guidelines suggest women with
icuspid aortic valve aortopathy, with ascending aortas4.8
m, be counseled against the high-risk pregnancy.
An important paper reviewing the Canadian experience
iscussed mortality in CHD and definitely shifted the
mphasis away from infants toward adults, with an increase
n age at death and a gradual decrease in mortality (115).
here were 71,686 CHD patients from 1987 to 2005 in the
uebec population who were studied for 982,363 patient-
ears. Factors contributing to decreased mortality in older
hildren and adolescents include earlier and more accurate
iagnosis, and refinement of selection procedures for surgi-
al or percutaneous interventions. The reduction in mortal-
ty observed in children over these years was not accompa-
ied by an increased mortality rate in adults. The mortality
ate in adults ages 18 to 64 years declined comparable to that
f the general population, suggesting that adults with CHD
enefited from the overall gains in population health. fiThis large study reports a reduction over time in infant
ortality and decreasing mortality rates in children and
dolescents. The population with congenital heart disease is,
herefore, growing and aging, with the burden of healthcare
ransitioning away from the child and toward the adult,
aising challenges that the healthcare community may need
o be prepared for in the allocation of resources.
eart Failure
ontinuous flow left ventricular assist devices (LVAD)
ignificantly improve outcomes in advanced heart failure
atients. Rogers et al. (116) assessed the impact of a
ontinuous flow device on functional capacity and heart
ailure-related quality of life using data from patients
nrolled in the HeartMate II (HMII) LVAD bridge to
ransplantation (BTT [n  281]) and destination therapy
DT [n  374]) trials. Compared with baseline measure-
ents, HMII patients experienced substantial improve-
ents in mean 6-min walk distance in DT patients and
ustained improvements from baseline in median Minne-
ota Living With Heart Failure and Kansas City Cardio-
yopathy Questionnaire overall summary scores in both
TT and DT patients. In an accompanying editorial,
tarling et al. (117) commented that LVAD therapy had
ntered a new phase with the introduction of continuous
ow devices, while acknowledging that patients implanted
ith a continuous flow LVAD still experience significant
unctional impairment and increased risk from infection,
evice malfunction, and stroke. Bleeding believed to be
elated to anticoagulation therapy coupled with bleeding
iathesis such as acquired von Willebrand syndrome is also
requently reported with continuous flow devices. To deter-
ine the prevalence of coagulation abnormalities, Uriel et
l. (118) performed a retrospective study in all 79 HMII
atients who underwent implantation over a 5-year period.
early half experienced significant bleeding episodes (with
astrointestinal bleeding being the most common event) at
n average of 112 183 days post-implantation. Compared
ith patients with a pulsatile device, transfusion require-
ents at heart transplantation were doubled in HMII
atients. High molecular weight von Willebrand factor
ultimers were reduced in all 31 HMII patients in whom
hey were measured, with recovery demonstrated in a
maller number who were restudied post-transplant. These
ndings support the notion of altering anticoagulation
herapy in HMII patents both during device support and
efore surgery. In an accompanying editorial, Miller (119)
ommented that the findings should lead to future trials
ssessing the effects on bleeding risk of monitoring von
illebrand factor levels in patients implanted with a con-
inuous flow device.
Borlaug et al. (120) sought to determine mechanisms
nvolved in exercise limitation and symptoms in patients
ith heart failure and preserved EF (HFpEF). They con-
rmed reduced exercise capacity and tolerance in HFpEF
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Highlights From JACC 2010 January 25, 2011:480–514atients compared with hypertensive subjects without heart
isease and compared with normotensive controls. The
FpEF patients had lower VO2 and cardiac index at peak
xercise and more severe dyspnea and fatigue at matched
ow-level workloads. Although endothelial function was
mpaired both in HFpEF patients and hypertensive subjects
ersus controls, blunted exercise-induced increases in chro-
otropy, contractility, and vasodilation and impaired dy-
amic ventricular-arterial coupling responses were seen only
n the HFpEF population. Exercise capacity was correlated
ith abnormalities in each component of CV reserve func-
ion, and HFpEF patients were more likely to display
ultiple abnormalities in reserve. These findings provide
vidence of depressed reserve capacity involving multiple
omains of CV function in HFpEF patients. In an accom-
anying editorial, Paulus (121) noted that, while there is
trong evidence for multiple causes of exercise intolerance in
FpEF patients, a steep LV diastolic pressure-volume
elationship was likely the dominant mechanism involved.
Maeder et al. (122) also compared exercise responses in
FpEF patients and healthy controls. While resting pul-
onary capillary wedge pressure (PCWP) was similar in
FpEF patients and controls, stroke volume index (SVI)
as lower, and systemic vascular resistance index (SVRI)
as higher in patients, and they stopped exercise at lower
ork rate. Although peak exercise PCWP was similar in
oth groups, peak SVI was lower and peak PCWP/work
ate ratio and SVRI were higher in HFpEF patients.
otably, while resting E/e’ from Doppler study was mod-
stly elevated in HFpEF patients, peak exercise E/e’ did not
iffer between the groups. Thus, HFpEF patients achieve a
imilar peak exercise PCWP to that of asymptomatic
ontrols, at a much lower workload in the setting of higher
VRI. In a related paper, Penicka et al. (123) determined
hat, in patients with unexplained dyspnea, evidence of an
levated PCWP could be demonstrated in about two-thirds
f patients during exercise, indicating the presence of
FpEF. Increased LV stiffness, dyssynchrony, and dynamic
itral regurgitation were the major mechanisms involved.
n an accompanying editorial, Lam (124) noted that, while
his study provided further evidence that HFpEF was a
requent cause of unexplained dyspnea, accurate diagnosis
as only the first step in the management of the patient and
ew evidence-based therapies that improve the natural
istory of this condition are badly needed.
The role of pre-clinical diastolic dysfunction on echocar-
iogram in the development of heart failure in diabetics was
xamined by From et al. (125). They identified diabetic
atients with a ratio of transmitral to mitral annular
f velocities of 15 and followed them from 2001 to 2007.
f the 1,760 diabetic patients, 23 patients had evidence of
re-clinical diastolic dysfunction. They observed that for
very 1 unit increase in the ratio of transmitral to a mitral
nnular Doppler velocities, there was a 3% increase in the
ncidence of heart failure (p  0.006), and that this was
ndependent of other traditional risk factors for heart failure. rhe cumulative probability of heart failure over 5 years for
iabetic patients with diastolic dysfunction was 36.9% as
ompared with 16.8% for patients without (p  0.001). In
n accompanying editorial, Greenberg (126) comments that
his study confirms the frequent presence of cardiac abnor-
alities in diabetic patients, and demonstrates their signif-
cance in leading to heart failure. However, he does not
elieve that this justifies the routine use of Doppler studies
n diabetic patients, but rather argues strongly for very
ntensive treatment of heart failure risk factors in this
opulation.
An additional paper dealing with diabetes related to the
revalence of cardiac events during different treatments
f hypertension. Weber et al. (127) analyzed data from the
CCOMPLISH (Avoiding Cardiovascular Events Through
ombination Therapy in Patients Living With Systolic
ypertension) study to determine whether the addition of
miodipine or hydrochlorothiazide to the angiotensin-
onverting enzyme blocker benazepril was more effective in
ecreasing CV events in diabetic patients. Comparable
lood pressures were obtained in both groups, whereas
vents were experienced by 8.8% of amiodipine patients
ersus 11% of patients receiving diuretics (p 0.003). Thus,
s was true of the ACCOMPLISH trial in general, com-
ining the calcium-channel blocker amiodipine with the
ngiotensin-converting enzyme inhibitor benazepril was
uperior to the combination with a diuretic for diabetic
atients.
To determine whether differences in beta-receptor spec-
ficities affect lung or vascular function in CHF patients,
abbour et al. (128) evaluated the respiratory, hemodynamic,
nd clinical effects of switching between beta-1-selective
nd nonselective beta-blockers in CHF patients and COPD
128). The 51 patients received dose-matched treatment
ith either carvedilol, metoprolol succinate, or bisoprolol
or 6 weeks before resuming their original beta-blocker.
hey found that N-terminal pro-hormone brain natriuretic
eptide and central augmented pressure were significantly
ower with carvedilol than with metoprolol or bisoprolol,
nd returned to baseline level on resumption of the initial
eta-blocker. In COPD patients, forced expiratory volume
n 1 second was lowest with carvedilol and highest with
isoprolol. Thus, switching between beta-1-selective and
he nonselective beta-blocker carvedilol, although well tol-
rated, resulted in demonstrable changes in airway function,
hich was most pronounced in COPD patients.
Cardinale et al. (129) evaluated anthracycline-induced
ardiomyopathy (AC-CMP) and its response to heart
ailure therapy in 201 consecutive patients with left ventric-
lar ejection fraction (LVEF) 0.45. They initiated enala-
ril, and if possible, carvedilol, promptly after detecting
mpaired LVEF. Patients were classified according to com-
lete, partial, or no response in LVEF. Overall, 85 (42%)
ere responders, 26 (13%) were partial responders, and 90
45%) were nonresponders. The likelihood of a favorable
esponse progressively decreased as the time from chemo-
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January 25, 2011:480–514 Highlights From JACC 2010herapy end to the start of heart failure treatment increased;
o complete recovery of LVEF was observed after 6
onths. Responders also showed a lower rate of cumulative
ardiac events. Thus, early initiation of neurohormonal-
locking therapy in patients having AC-CMP results in
ecovery of LVEF and a reduction in cardiac events.
Sezai et al. (130) compared the effects of infusing 0.02
g/kg/min of human atrial natriuretic peptide (hANP)
ersus saline in patients with LVEF 0.35 undergoing
ABG in the NU-HIT (Nihon University Working Group
tudy of Low-Dose Human ANP Infusion Therapy During
ardiac Surgery) study. While early post-operative mortal-
ty was not significantly affected by treatment, perioperative
omplications were significantly less frequent and cardiac
eath-free rate at 5 to 8 years post-operatively was signifi-
antly lower in the hANP group. Post-operative EF was
lso significantly higher, BNP levels significantly and renal
unction appeared better in hANP-treated patients in the
rst post-operative year. In their accompanying editorial,
oors and van Veldhuisen (131) note that while the
U-HIT study results were consistent with other previously
ublished reports about the use of natriuretic peptides
uring surgery, definitive evidence of a favorable effect on
enal function and clinical outcomes required a larger
ell-designed trial. They concluded that the favorable
esults presented in this article should provide the stimulus
o proceed with such a trial.
A paper by Verhaert et al. (132) describes long-term
mean 3.6 years) clinical and echocardiographic follow-up in
13 patients who underwent CRT. In patients with event-
ree survival, left ventricular end-systolic volume index
LVESVI) decreased significantly in the first 6 months,
hereas patients with adverse clinical outcomes had no
hange in LVESVI. These data demonstrate the value of
easuring LVESVI at baseline and follow-up as a powerful
redictor of event-free survival after CRT.
A study by Derval and Jais (133) sought to evaluate the
elationship between LV pacing site and the hemodynamic
esponse to CRT. The investigators assessed 11 pre-
etermined pacing sites and assessed several measures of LV
unction for each site. Pacing at the optimal site significantly
mproved LV function compared with coronary sinus pac-
ng, improving maximum dP/dT by 2.
ealth Services Research
isk adjustment is central to the concepts of score-carding
nd quality improvement, because some patients are sicker
han others and would be expected to have worse outcomes
rrespective of treatment. Clinicians have perennial concerns
hat the standard data elements used in risk adjustment
cores might not fully capture how sick the patient really is.
his is a particular issue for older patients, many of whom
ail “the eyeball test.” Chaudhry et al. (134) abstracted charts
f older patients with heart failure to capture data on their
obility and cognitive function, 2 elements that are not hvailable in discharge codes, and found that each signifi-
antly improved risk assessment when added to standard
ata elements from history, physical, and laboratory find-
ngs. These results are plausible, and suggest we need ways
o capture a clinician’s gestalt about the functioning of older
atients in records of care.
Cardiac noninvasive tests have continued to increase
aster than other forms of medical care. Serial testing to
onitor patients over time constitutes a large fraction of test
se. Shah et al. (135) studied patterns of cardiac stress
esting after coronary revascularization procedure and found
hat most patients were tested at least once within 24
onths after their procedure. Interestingly, test use spiked
t 6 and 12 months post-procedure, suggesting these stress
ests were done at a routine visit, not based on recurrent
ymptoms as recommended in appropriate use criteria.
In the mind of the public, stress and psychological factors
ead to heart disease, but the relationship has been difficult
o assess in epidemiologic studies. Long-term follow-up of
en 18 to 20 years of age who had psychological tests done
s part of a medical examination for compulsory military
ervice in Sweden showed that anxiety disorders were
ndependently associated with incident heart disease de-
ades later, independent of other risk factors (136). A
eta-analysis of 20 other epidemiologic studies also found
hat anxiety disorders increased the incidence of coronary
isease over the subsequent 11 years (137). Whether these
ssociations reflect a causal pathway, such as chronic sym-
athetic activation, or whether anxiety is merely a marker
or other factors, is not established.
If anxiety is bad for the heart, might a glass of wine with
inner help reduce stress and risk of cardiac disease? The
ffect of alcohol on the heart has been controversial. A study
ased on the National Health Interview Study (138) sug-
ests that light or moderate alcohol intake was associated
ith lower cardiac risk than either abstaining from alcohol
n the one hand or heavy alcohol intake on the other (7
rinks per week for women, 14 drinks per week for men).
he U-shaped relationship between alcohol consumption
nd heart disease may make public health education tricky,
ut fits well with advice to drink in moderation.
A paper by Aboyans et al. (139) reports on the relation-
hip between location of peripheral arterial disease (PAD)
nd MACE. The authors studies 400 PAD patients. Prox-
mal PAD (aortoiliac disease) was associated with a signif-
cantly worse prognosis compared with distal PAD. Ad-
usted for comorbidities, proximal PAD patients were 3
imes more likely to experience a MACE event compared
ith distal PAD patients. There was also a significantly
igher rate of mortality in patients with proximal PAD.
Freeman et al. (140) examined the outcome for330,000
atients who underwent an ICD implantation during the
ears 2000 to 2008, demonstrating a strong relationship
etween hospital ICD volume and procedural complica-
ions. The adjusted OR of any adverse event was 1.26 for
ospitals in the lowest volume quartile compared with
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Highlights From JACC 2010 January 25, 2011:480–514ospitals in the highest volume quartile. This relationship
as strongest for biventricular devices (OR: 3.22) but also
ignificant for single-chamber ICD procedures (OR: 1.10).
he authors suggest that implantation of these devices may
e performed more safely at high-volume centers.
oronary Calcium
provocative manuscript and editorial reports by Gottlieb
t al. (141) on the relationship between coronary calcium
core and the presence or absence of obstructive coronary
esion in patients undergoing 64-slice multidetector coro-
ary computed tomography angiography. Although patients
ith a calcium score of zero were less likely to have a
oronary obstruction 50%, the absence of calcium by
ultidetector coronary computed tomography angiography
id not rule out obstructive CAD. In the patients without
oronary calcium, 19% had a least 1 lesion with 50%
tenosis. In 64 totally occluded vessels, 20% had no calcium.
Few data are available regarding quality and outcome
easures in patients with CV disease treated in the outpa-
ient setting. Therefore, the American College of Cardiol-
gy established within the NCDR the PINNACLE (Prac-
ice Innovation and Clinical Excellence) program. The
erformance measures for the first nearly 15,000 patients
nrolled were presented by Chan et al. (142) regarding
AD, heart failure, and AF. Compliance with performance
easured in these 27 U.S. practices ranged from a low of
3.3% of CAD patients screened for diabetes to a high of
6.7% of heart failure patients with blood pressure assess-
ent, and was moderate (70% to 90%) for most perfor-
ance measures. Thus, this registry established for the first
ime the feasibility of assessing compliance with perfor-
ance measures in the outpatient setting, and showed both
oderate compliance as well as the opportunity for im-
rovement. In an editorial, Rao (143) commented that it
rovided an opportunity to evaluate the quality of medical
are in a longitudinal perspective over time.
With increasing emphasis upon performance measures,
here is critical need to identify risk factors for PCI so as to
ssist in decision making, compare provider performance,
nd assist comparative effectiveness research. Peterson et al.
144) utilized data from the NCDR to develop risk score for
CI from 588,000 procedures (144). They found that
linical factors were significantly associated within hospital
ortality, whereas angiographic factors provided only mod-
st incremental information. They developed a simplified
CDR risk score based on 8 pre-procedural factors that had
n excellence discrimination (see index 0.93). In an accom-
anying editorial, Kereiakes (145) commented that this
imple 8-variable model accurately predicted the risk of
eath to 30 days PCI in Medicare patients, and should be
ery clinically applicable. However, he pointed out that the
ontinuing development of interventional cardiology will
equire additional risk scores in the future. lQuestions exist on whether long-term intensive endur-
nce training can have adverse effects upon LV structural
unction. Therefore, Pelliccia et al. (146) participated in the
xtreme endurance conditioning necessary to compete un-
nterrupted in 2 to 5 consecutive Olympic games. No
ardiac events or new CV conditions were diagnosed. In
ddition, global LV systolic function was unchanged, and
all motion abnormalities were absent. Thus, in this group
f young Olympic athletes, long-term uninterrupted endur-
nce training was not associated with deterioration of LV
unction. In an accompanying editorial, Bhella and Levine
147) commented that the possibility of “athletes heart” has
een suspected in the past, and has been supported by the
emonstration of post-exercise elevations and cardiac spe-
ific markers and changes in cardiac structure. However,
hey endorse that the report by Pelliccia et al. (146) is quite
eassuring that any abnormalities incurred in intense pro-
onged endurance training are likely reversible and relatively
enign.
enetics/Genomics
f you are questioning whether to skip over this genetic
ection because you think it does not apply to your clinical
ractice, we ask you to reconsider. The Journal strives to
ublish significant findings in the area of CV genetics that
ake a difference in clinical practice. This year “The Best of
ACC” focuses on how genetics improves patient care and
anagement, and defines how genetic variants alter CV
isk.
Hofman et al. (148) report a 12-year look at a clinical
anagement of probands and relatives with congenital long
T syndrome (LQTS), Brugada syndrome (BrS), and
atecholaminergic polymorphic ventricular tachycardia
CPVT) in the context of genetic testing. First-degree
elatives of an affected person with an inherited arrhythmia
yndrome carry an 50% risk of carrying the mutation
149). The risk of a lethal event with or without this specific
utation in an affected relative is less clear. Moreover, the
esponse to therapy has been shown to be genotype specific
or LQTS (2–4). Surprisingly, 59% of the patients in this
etrospective analysis had a QTc 460 ms, and would have
een missed for LQTS if genetic testing were not per-
ormed. These patients can be provided with a series of
ifestyle instructions and a set of QT-prolonging drugs to be
voided.
CPVT does not have 100% penetrance (similar to
QTS). A negative exercise test does not rule out that the
atient carries a mutation associated with CPVT. Thus
gain, genetic testing was informative (150). Mutations in
CN5a have been associated with BrS. However, these
utations in SCN5a account for roughly one-third of
utations associated with BrS. Unlike LQTS and CPVT,
he treatment options for BrS are limited (151). Thus, the
dvantages and disadvantages of genetic testing for BrS are
ess clear. Schwartz (152) provides a well-written editorial
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January 25, 2011:480–514 Highlights From JACC 2010ith a historical reminder that, in 1980, a hypothesis was
resented that patients affected by LQTS had a normal QT
nterval. This 12-year retrospective study supports that
ypothesis.
A second LQTS paper published highlights how a
isk-conferring modifier gene in a large cohort of LQTS
ndividuals increases the incidence of cardiac events (153).
his work follows others showing modifier genes in the
itric oxide synthase (NOS) signaling pathway in persons
ith LQTS; NOS1AP encodes the protein CAPON,
hich is an adaptor protein linking neuronal NOS with
caffold and signaling ligands, including dystophins. Next-
eneration sequencing will be informative in identifying
ther modifier genes in the probands and families with
nherited arrhythmic disorders. Identification of modifier
enes for inherited arrhythmic disorders is a significant area
f study to help identify risk of major CV events and death
n these patients.
A selected meta-analysis from Benn et al. (154) showed
hat the loss of function 49L allele of proprotein convertase
ubtilisin/kexin type 9 (PCSK9) was associated with a
eduction in LDL cholesterol of 11% to 16%. This loss of
unction allele is found in 2% to 3% of the general
opulation. PCSK9 is a protease that reduces LDL receptor
evels and thereby increases plasma LDL cholesterol. This
tudy determined the effect of this loss of function allele in
CSK9 on LDL cholesterol and the risk of ischemic heart
isease and mortality. A significant association between
arriers of the risk allele and reduced risk of ischemic heart
isease was identified in only 1 of the 3 cohorts studied,
erhaps because of environmental differences between the
ohorts, including statin use, and changes in risk factors that
ay have altered the effects of the loss of function PCSK9
isk allele on ischemic heart disease. This meta-analysis
emonstrated that the influence of genotype on CV disease
isk depends on modifiable risk factors, environment and
harmacological therapy. Newton-Cheh and Smith (155)
rovided an accompanying editorial that discusses how
enetic associations can be used to judge whether a clinical
rait is a causal factor in disease development. The pipeline
f deoxyribonucleic acid variants in genes associated with
ltered lipid metabolism continues to expand exponentially
156).
A pharmacogenomics meta-analysis by Hulot et al. (157)
howed that reduced CYP2C19 function exposes
lopidogrel-treated patients to excess CV risk and mortality.
lopidogrel requires transformation to an active metabolite,
hich is regulated in part through CYP2C19. Risk for stent
hrombosis increases by 3- to 6-fold with a genotype
ositive for loss of function mutations in the CYP2C19.
he study also suggests that proton pump inhibitors in-
rease risk for CV events when taken with clopidogrel,
lthough the variability in the studies was high, suggesting
hat more information is needed in these studies including
enotypes and severity of disease. aContinuing along the lines of CAD, Dandona et al. (158)
eport that the common variant in 9p21 predicts the severity
f atheroma burden. This study provides evidence that gene
osage of the risk allele for rs1333049 (homozygosity vs.
eterozygosity) was associated with severity of CAD in
ounger patients at the time of mitral catheterization and in
cohort of older persons. Importantly, no association was
ound between 9p21 and MI. The mechanisms that are
esponsible for increased risk of CV disease due to regions
ear 9p21 are still not understood, and this better defines
he role of atherosclerosis burden and risk of MI. An
ditorial by Anderson and Horne (159) discusses the po-
ential role of 9p21 as a potential initiator, promoter, or
recipitator of CAD. The underlying mechanisms of the
isk allele on the 9p21 locus are not likely linked to
nflammation or rupture of a fibrous cap leading to MI.
A state-of-the-art review by Baird (160) points out that
he underlying cause of 30% of ischemic strokes remains
nknown, and the diagnosis for stroke is accurate only
70% of the time. It is well known that stroke is heritable,
nd a family history of stroke increases one’s risk by 2- to
-fold (161). Monogenic disorders and causative genes/
hromosomal locations associated with stroke are reviewed
s well as findings from genome-wide association studies.
he genome-wide association studies have identified loci
hat are associated with increased risk for stroke that also
redispose risk for atrial fibrillation. Hope in the arena of
mproved diagnostic platforms for stroke may be near;
essenger RNA and proteomic profiling to identify targets
n the blood after ischemic stroke are reviewed.
The field of genetics is changing our overall understand-
ng of dilated cardiomyopathy. Lakdawala et al. (162)
eported that a mutation in alpha-tropomyosin in 2 unre-
ated families is associated with a distinct age-dependent
ilated cardiomyopathy that can be lethal early in life. This
s the first evidence to supporting a role for tropomyosin in
ilated cardiomyopathy that provides multigenerational
amily data and contractility assays in vitro. Treatment with
otential for improvement in a subset of affected infants
ncreasingly moves the bar for improvement in quality
atient care. The inclusion of state-of-the-art contractility
ssays in vitro build the evidence that this specific mutation
eads to decreased functional properties of tropomyosin.
ommentary on how deoxyribonucleic acid variants in
arcomeric proteins alter the structure and function of the
arcomeric protein to influence the final common pathway
f hypertrophic cardiomyopathy versus dilated cardiomyop-
thy is expertly laid out for the clinician and scientist in an
ditorial by Tardiff (163).
The Z disc is a region that joins the contractile apparatus
o the cytoskeleton. Using a genome-wide linkage approach
n 4 families, Chiu et al. (164) provide evidence that
utations in alpha-actinin 2 are associated with hypertro-
hic cardiomyopathy. The mutations in alpha-actinin 2 are
ithin a number of important functional domains. Anccompanying editorial by Bos and Ackerman (165) points
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Highlights From JACC 2010 January 25, 2011:480–514ut that clinical genetic testing currently includes a 9-panel
creen for sarcomeric or myofilament genes, which explains
oughly 65% of genetic hypertrophic cardiomyopathy. The
iscovery of new genes will improve the genetic screening
or all and aid in our overall understanding of hypertrophic
ardiomyopathy. They also point out that alpha-actinin 2
lso binds to ion channels and serves as a bridge to calcium
hannels and mutations may also increase risk for other
V-related endpoints.
Girolami et al. (166) undertook a novel direct sequencing
creening of 8 genes in 488 unrelated hypertrophic cardio-
yopathy patients, showing that persons harboring triple
arcomeric gene mutations are rare, and that this led to a
ignificantly increased risk of end-stage disease and ventric-
lar arrhythmias. These findings alert us that multiple rare
ariants do modulate the CV phenotype, as pointed out in
n accompanying editorial by Hershberger (167). Exome
equencing and the release of the 1,000 genomes data will
rovide more information on rare variants. How these
ariants may collectively influence disease and/or interact
ith the environment is an area nearly untapped in the field
f CV medicine.
Arrhythmogenic right ventricular cardiomyopathy is be-
ieved to be inherited in a moderate percentage of cases.
ultiple genes, primarily involving desmosomal proteins,
ave been believed to be causative in arrhythmogenic right
entricular cardiomyopathy. However, Xu et al. (168) iden-
ified 21 variants of plakophilin-2 in 38 of 198 probands
19%), in 9 of whom compound heterozygosity was present.
n addition, digenic heterozygosity was identified in 16 of
he 38 subjects. Accordingly, these data demonstrate that
he genetic basis of arrhythmogenic right ventricular car-
iomyopathy includes compound and digenic heterozygos-
ty, and demonstrated that simple single gene analysis would
e inappropriate in attempting to define the nature of the
enetic and clinical basis of this disorder.
Achieving the optimal dose of warfarin without encoun-
ering either bleeding or thrombosis is often problematic.
olymorphisms in 2 genes regulating the effect of warfarin
CYP2C9 and VKORC1) have recently been identified.
pstein et al. (169) performed a clinical trial to document
hether commercially available phenotype testing of warfa-
in patients for these 2 polymorphisms could enhance the
linical administration of this drug. They demonstrated 28%
eduction in hospitalizations for bleeding or thromboembo-
ism in the 6-month follow-up of patients receiving warfarin
n whom the genotype had been determined and presented
o the referring physician. Interpretation of these data was
omplicated by the historical control group, the genotype
nformation was not conveyed until 3 months after starting
herapy, and the physicians participating were aware that
heir treatment was being observed. In an accompanying
ditorial, Ginsburg et al. (170) indicate that, although this
tudy has flaws, the results suggest that genotype-guided
arfarin therapy may result in clinically meaningful reduc-ions in patient outcomes in a “real world” setting. oA paper by Zhang et al. (171) describes the association
etween hypertension and a naturally occurring genetic
ariation in the promoter of chromogranin B, a 33-amino
cid neuropeptide associated with catecholamine storage
esicles. The researchers conclude that this variation con-
ributes substantially to the risk for human hypertension,
rimarily through responses to environmental stress and
ay also explain sex differences in the rate of hypertension.
re-Clinical Research
he role of specific cell subtypes in ventricular remodeling
fter MI. After MI, acute inflammatory responses and
ealing are regulated by a complex sequence of events
nvolving multiple cell types. Dissecting out the components
f these processes may provide new therapeutic targets to
mprove cardiac structure and function after acute MI.
Panizzi et al. (172) examined the role of 2 subsets of
onocytes. They previously found inflammatory monocytes
ith the marker Ly-6Chi predominate during the first 4
ays after infarction, whereas Ly-6Clo monocytes that are
mportant for angiogenesis and repair are prevalent during
he healing phase. Increasing baseline circulating levels of
y-6Chi monocytes in mice, causes persistent inflammation
days after MI, with increased expression of inflammatory
enes, protease, and phagocytosis activity with worse MRI
F after 21 days. Adverse remodeling related to the subset
f Ly-6Chi monocytes may be a potential therapeutic target.
ardilo-Reis et al. (173) in an editorial, note there are
imilar subsets of monocytes in humans. The major subset
n peripheral blood are CD14CD16 monocytes, which
re similar to the inflammatory Ly-6Chi monocytes. These
inflammatory” monocytes are important for inflammation,
hagocytosis and proteolysis. In contrast, CD14CD16
onocytes are similar to Ly-6Clo monocytes, and are
nvolved in healing, repair, collagen, and angiogenesis. It
ill be important to determine how switching between
hese subtypes of monocytes is regulated, which may lead to
reatments that maximize their beneficial, while minimizing
dverse effects after recovery from MI.
Cell therapy in MI continues to garner interest despite
heir mixed success in clinical studies. Dubois et al. (174)
ostulated varying efficacies of different progenitor cells.
igs were randomly assigned to receive intracoronary autol-
gous late-outgrowth endothelial progenitor cells (EPC),
llogeneic mesenchymal stem cells (MSC), or vehicle (con-
rols) 1 week after occlusion of the left circumflex coronary
rtery. Pigs receiving EPCs had improved LV remodeling
ith smaller end-systolic volumes by MRI after 6 weeks,
ith smaller transmural infarct size, higher angiogenic
lacental growth factors and increased vascular density in
he border zone. The success of EPCs in this pre-clinical
odel may be related to better engraftment of EPCs (but
ot MSCs) late after infarction, and that late outgrowth
PCs are progenitors of endothelial cells, whereas early
utgrowth EPCs used in most clinical studies are monocytic
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January 25, 2011:480–514 Highlights From JACC 2010rogenitor cells. Although it was a small study with a single
ose of EPCs, these results may have potential applications
or treating chronic ischemic cardiomyopathy.
In the setting of pre-clinical translational biology, Kim et
l. (175) published data to support a role for human
eripheral blood-derived CD31 cells in the treatment of
schemic peripheral vascular disease. The work by Kim et al.
175) shows clear improvements in capillary density, and
ircumvents ex vivo culture issues, given the abundance of
D31 circulating cells in humans. Moreover, blood per-
usion was improved and limb loss was attenuated. Thus,
mprovements in functional endpoints were attained along
ith an approach that appears feasible for translation to
umans. Questions as to whether these cells are actually
erging with the endothelium are not fully addressed, as
ointed out by Simari and Gulati (176) in the accompany-
ng editorial. Cell therapy success will depend not only on
mprovement of perfusion but also on manufacturing and
elivery of these cells, as well as the potential to merge cells
ith systemic delivery of enhancing pharmacological agents.
ovel target sites for treating cardiomyopathy. PRE-
LINICAL STUDIES. Ogino et al. (177) examined the bene-
cial effects of erythropoietin (EPO) receptor activation in
eart failure related to renal dysfunction. In mice undergo-
ng 5/6 nephrectomy, renal dysfunction, anemia, cardiac
ypertrophy, leukocyte infiltration, and oxidative damage
ith cardiac fibrosis developed after 8 weeks. These abnor-
alities progressively worsened from 8 to 12 weeks in rats
iven saline, but were attenuated in rats treated with either
ecombinant human erythropoietin (rhEPO) (5,000 IU
wice a week for 4 weeks), or asialoerythropoietin (AsEPO),
n EPO derivative that does not alter hemoglobin. Both
PO and AsEPO effectively attenuated nephrectomy-
nduced decreases in sarcomeric proteins and decreased
nflammatory cytokines and lipid peroxidation. Thus, EPO
eceptor activation is cardioprotective to decrease inflamma-
ion, oxidative damage, and fibrosis independently of any
ffects on anemia. van der Meer et al. (178) discussed
linical studies that have shown adverse effects from treating
nemia in chronic kidney disease with EPO. The increase in
emoglobin is associated hypertension, increased viscosity,
nd an increased risk for stroke and mortality. The devel-
pment of AsEPO by removing sialic acid moieties in-
reases clearance to attenuate hematopoiesis without losing
issue protective effects. This may provide an alternative and
afer approach to activate EPO receptors while retaining the
eneficial cardioprotective effects.
Rajesh et al. (179) examined a novel target to treat
iabetic cardiomyopathy, in a mouse model of type I
iabetes (intraperitoneal streptozotocin for 5 days). Canna-
idiol, a nonpsychoactive constituent of marijuana with
nti-inflammatory effects, improved LV function, decreased
xidative/nitrosative stress with decreased reactive oxygen
pecies generation from mitochondria, decreased inflamma-
ion, cell death from apoptosis, and decreased cardiac
brosis. This study is attractive because cannabidiol is ponpsychoactive, well tolerated, and safe in humans, and
as been approved (in Canada) for the treatment of pain and
pasticity for multiple sclerosis.
In another study, Zheng et al. (180) used the antibiotic
oxycycline to target a novel site in a mouse model of
esmin-related cardiomyopathy. Transgenic mice with car-
iac overexpression of abnormal B-crystallin form protein
ggregates with LV hypertrophy, progressive heart failure,
nd increased mortality. Doxycycline added to the drinking
ater at 8 or 16 weeks of age resulted in decreases in
ypertrophy, protein aggregates, and ubiquinated proteins.
illarreal and Lew (181), in an editorial comment, discuss
he emergence of drugs to target misfolded proteins to
revent the formation of insoluble protein aggregates in
onditions such as Alzheimer’s disease and cardiomyopa-
hies. The heart continuously synthesizes and degrades
roteins with a turnover rate of 2% per day. That can lead
o the formation of damaged or misfolded proteins, which
re identified and eliminated by the uniquitin-proteasome
ystem (UPS). The finding by Zheng et al. (182) that doxy-
ycline, a safe antibiotic, decreased cardiac protein aggregate
ormation to attenuate cardiomyopathy is intriguing.
athogenesis of atherosclerosis. There is a dearth of data
n the long-term vascular effects of radiotherapy in humans.
alle et al. (183) compared arteries exposed to radiation
reatment in 13 patients with nonradiated donor artery from
he same person (183). There was evidence of sustained
nflammation both early (4 to 7 weeks) and late (20 to 500
eeks) after radiation. Increased expression of several genes
elated to inflammation in radiated arteries was found and
onfirmed by immunohistochemistry. There was sustained
ctivation nuclear factor-kappa B (NF-B), suggesting a
nique role of this transcription factor for sustaining inflam-
ation. Although this was a small study, Weintraub et al.
184) note this provides the first direct evidence of chronic
p-regulation of NF-B in human arteries exposed to
adiation. This raises several important questions, such as
he mechanisms for radiation to up-regulate NF-B, if this
nvolves oxidative stress, and if changes in small conduit
rteries also occur in larger sized arteries that underlie most
V events.
Gene therapy has been limited by finding safe and
ffective means for delivery without systemic effects. Suzuki
t al. (185) used ultrasound microbubbles to deliver inter-
ering ribonucleic acids (siRNA) targeting intercellular ad-
esion molecule (ICAM) -1 using a transducer placed
irectly over the injured femoral artery of mice that sup-
ressed neointimal formation and inflammation without
ystemic effects. Kupatt (186), in an editorial, reviews the
bstacles for in vivo gene therapy in atherosclerosis. This
as included difficulties in achieving in vivo transfection of
he endothelium, developing suitable viral vectors to pro-
uce long-term expression without integration into nontar-
eted sites with side effects, and limitations in transfection
fficiency of liposomal delivery systems. He notes this study
rovided proof of principle that siRNA can be selectively
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Highlights From JACC 2010 January 25, 2011:480–514elivered with targeted ultrasound to injured endothelium,
o attenuate inflammatory processes and intimal hyperplasia
or up to 1 week after injury.
The genetic basis of atherosclerosis is intriguing but
nigmatic. Gonzalez-Navarro et al. (187) found a mecha-
istic link between the CDKN2a gene that encodes tumor
uppressor ARF and atherosclerosis. Deficiency in p19ARF
ncreased aortic atherosclerosis 1.5-fold in association with
ecreased apoptosis in the atherosclerotic lesions in mice
eficient for apolipoprotein E. This was not observed in less
therogenic regions. Macrophages and vascular smooth
uscle cells from p19ARF-deficient mice also showed de-
reased apoptosis in vitro, suggesting that gene is associated
ith the progression, rather than initiation of atherosclero-
is by limiting apoptosis in the plaque. Wessely (188), in an
ditorial comment, notes the emerging understanding of the
ole of cyclin-dependent kinase, and the use of cyclin-
ependent kinase inhibitors to inhibit cell cycle regulation
n CV diseases (188). This study supports the hypothesis
hat cyclin-dependent kinase inhibitors may be useful for
nhibiting vascular inflammation and proliferation in the
rogression of atherosclerosis.
echanisms of AF. Structural remodeling of the atrium
ith interstitial fibrosis increases conduction heterogeneity
hat may be a substrate for developing AF. Adam et al.
189) found increased interstitial fibrosis in the left atrial
ppendage of patients undergoing valvular surgery with AF
ompared with tissue from patients in sinus rhythm. There
as up-regulation of connective tissue growth factor, and
ncreases downstream of N-cadherin and connexin 43,
hich play important roles in the formation of gap junc-
ions. Neonatal mouse myocyte and fibroblast studies sup-
orted the role for angiotensin II to activate connective
issue growth factor by Rac1 and NADPH oxidase, to
ncrease gap junction proteins as a potential mechanism for
trial structural remodeling. Liao (190), in an editorial,
otes Rac1 and connective tissue growth factor may provide
n important link between atrial fibrosis and AF, and
rovide a rationale for angiotensin receptor blockers or
tatins to interrupt atrial remodeling and AF.
iomarkers. It is well known that activation of the renin-
ngiotensin system is essential for maintaining arterial blood
ressure within the normal range. Tomaschitz et al. (191)
easured plasma aldosterone and plasma renin concentra-
ion in 3,000 Caucasian patients, one-third of whom had
esistant hypertension. In the highest quartile of the
ldosterone-renin ratio, 13% had elevations great enough to
ustify with a clinical workup of primary aldosteronism. The
igher the decile, the more the rise in blood pressure,
rrespective of confounders such as age and renal function.
n an accompanying editorial by Bravo et al. (192), they
elieve this is the first study that demonstrates the relation-
hip of aldosterone-renin ratio to central blood pressure,
ften now accepted as the “true” blood pressure. They
uggest studies such as this will lead to consideration of a dider use of aldosterone antagonists in patients with
ypertension.
Acute pulmonary embolism is a fairly frequent CV
mergency that requires not only rapid diagnosis but also
isk stratification as well. However, risk stratification of
nitially normotensive patients is lacking. Heart type fatty
cid binding protein (HFABP) is a sensitive marker of
yocardial necrosis that is released from damaged myocytes
ithin 1 to 3 h. Dellas et al. (193) studied 126 normotensive
ulmonary embolism patients, of whom 7% suffered a
atastrophic event within 30 days. An elevated HFABP was
ssociated with a 16-fold increased likelihood of a major
omplication at 30 days. It was more sensitive and specific
han troponin and BNP. In an accompanying editorial,
oldhaber (194) suggests pairing the measurement of
FABP with troponin to create a large database, but
elieves that HFABP is an excellent addition to the arma-
entarium of clinical assessment, imaging, and biomarker
valuation of patients with pulmonary embolism.
McKie et al. (195) tackled the issue of screening healthy
ormal subjects and stage A/B heart failure patients for
rognosis. The NT-proBNP was not predictive of death or
V events in the healthy normal subgroup. However, in
atients with stage A/B heart failure, there was a strong
ssociation between these peptides and risk of death, heart
ailure, cerebrovascular accident, and MI. In an editorial by
o and Levy (196), they make note of some limitations in
he study regarding the healthy normal subgroup as not
eing quite the same as the general population—as the
ontrols were referred to echocardiography. They go on to
uggest that understanding the role of biomarkers as tools to
dentify high-risk patients will allow us to effectively target
reatment strategies in the future.
Kalogeropoulos et al. (197) explored the Health ABC
Health, Aging, and Body Composition) and found that
hen added to the previous risk factor model, inflammatory
iomarkers, especially interleukin-6, improved the model
or predicting heart failure. The associations were similar
cross sex and race. In an accompanying editorial, Cohn et
l. (198) speaks to the important issue of whether exami-
ation of statistical associations in population risk can be
linically useful. Thus far, there has been little evidence that
he inflammation associated with these biomarkers is caus-
tive and needs to be treated. They conclude that it is time
o initiate and document the effectiveness of efforts to
dentify early stages of CV disease in attempt to reduce overt
anifestations of disease.
Clinical decision limits for cardiac troponins levels have
oved progressively toward lower concentrations. Bonaca et
l. (199) investigated the prognostic implications of low-
evel increases in cardiac troponin I using a current gener-
tion sensitive test in patients with suspected ACS. They
pplied decision limits at the 99th percentile of the reference
imit (0.04 g/l). These low level values above the 99th
ercentile were able to identify patients at higher risk of
eath/MI at 30 days. In an accompanying editorial, Jesse
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January 25, 2011:480–514 Highlights From JACC 2010200) stated that in the “old days” when troponin was a
imited assay, it was a great test because, when used in the
ppropriate context, it markedly improved diagnosing MI.
s troponin assays have improved in threshold of detection,
mprecision has also increased, and higher sensitivity has
ecome a double edged-sword and created problems in
pecificity.
Kim et al. (201), as part of the Women’s Health Initiative
ormone trials sought to investigate whether multiple bi-
markers contributed to improved CAD risk prediction in
ost-menopausal women compared with traditional risk
actors. Eighteen biomarkers were tested in a nested case-
ontrol study that included 321 patients with CHF and 743
ontrols. The biomarker addition gave a net reclassification
mprovement of 6.45% over traditional risk factors. The 5
est biomarkers were interleukin-6, d-dimer, factor VII,
on Willebrand factor, and homocysteine. C-reactive pro-
ein achieved only borderline significance. Wang (202)
oints out in an accompanying editorial that biomarkers
hat lead to refinement of risk estimates might aid treatment
ecisions. This does not, he goes on to say, mean we should
se routine screening of a panel of biomarkers at the present
ime, as risk classification is unlikely to change significantly.
Ranolazine is believed to exert its anti-ischemic effects by
educing myocardial sodium and calcium overload and,
onsequently, ventricular wall stress. The BNP increases in
esponse to increased wall stress and is a strong risk factor in
CS. To this end, Morrow et al. (203), in the MERLIN–
IMI 36 (Metabolic Efficiency With Ranolazine for Less
schemia in Non-ST Elevation Acute Coronary–
hrombolysis In Myocardial Infaction 36) trial, examined
he interaction between BNP and the effect of ranolazine in
atients with ACS as part of a randomized, blinded,
lacebo-controlled trial. There results indicated that rano-
azine might work better in high-risk patients with ACS,
dentified by elevated BNP levels (80 pg/ml). In an
ccompanying editorial, Califf et al. (204) comment that,
hile the report does not provide definitive evidence that
anolazine should be used in patients with ACS and
levated BNP levels, the findings do warrant a prospective
linical trial.
Accurate CV risk prediction is difficult in elderly people.
eFilippi et al. (205) sought to determine whether serial
easurement of NT-proBNP in community dwelling el-
erly people would provide additional information above
raditional risk factors. The NT-proBNP was measured at
aseline and 2 to 3 years later in almost 3,000 community-
welling older adults free of heart failure. The NT-proBNP
n the highest quintile (267 pg/ml) was independently
ssociated with greater risks of heart failure, with an
nflection point of 190 pg/ml. Patients with an initially high
T-proBNP who had a 25% increase (40%) in a later
ample, were at higher risk for heart failure.
Risk stratification of ACS is increasingly dependent on
easurement of biomarkers. To this end, Weir et al. (206)tudied soluble ST2, a member of the interleukin-1 receptor Samily, in 100 patients admitted with MI and LV dysfunc-
ion, randomly assigned to receive eplerenone or placebo.
sing serial MRI scans, the authors were able to connect
he fact that soluble ST2 concentrations at the time of
nrollment were strongly predictive of future infract remod-
ling. Of note, a post-hoc observation suggesting that the
nti-remodeling benefits of eplerenone were mainly re-
tricted to patients with a high soluble ST2 concentration at
he time of enrollment. As pointed out by Moore et al. (207)
n an editorial, this work suggests the potential to use
iomarkers to identify patients at highest risk for remodel-
ng, who are the same patients most likely to respond to
nti-remodeling therapies like eplerenone.
Questions continue regarding the ability to use natri-
retic peptides to guide the treatment for chronic CHF.
ainchbury et al. (208) address this question in the
ATTLESCARRED (NT-proBNP Assisted Treatment
o Lessen Serial Cardiac Readmissions and Death) trial.
hey randomly assigned 364 patients to NT-proBNP–
uided therapy, intensive clinical management, or usual
are. One-year mortality was less with either NT-proBNP
r clinically guided treatment over usual care (9.1 vs. 18.9;
 0.03), but at 3 years, mortality was reduced with
ormone-guided treatment only in patients 75 years of
ge. Thus, while demonstrating a benefit for natriuretic
eptide-guided therapy at 1 year, this study showed value
or this strategy at 3 years only for patients75 years of age.
n an accompanying editorial, Maisel (209) pointed out that
he BATTLESCARRED trial shared all of the challenges
onfronting biomarker-guided therapy of heart failure; it
ppeared that future research would determine whether
uch a strategy would be ready for prime time clinical use.
ardiac Imaging
ecent work has confirmed that coronary calcium scoring
ermits further risk stratification on top of risk engines such
s the Framingham Risk Score (210). Min et al. (211)
emonstrated that, in 25% of patients with normal calcium
can (score 0), an abnormal calcium scan developed over
ime; the time to conversion was 4.1 0.9 years, suggesting
hat repeat scanning in patients with calcium score 0 is not
eeded within 4 years of the index scan (212). These
ndings would support risk factor modification and aggres-
ive medical therapy in some patients, although prediction
f conversion appeared difficult. In addition, a comprehen-
ive literature review revealed that the currently available
tudies could not demonstrate regression of coronary artery
alcium after medical interventions (e.g., statin therapy)
213).
Although calcium scans identify atherosclerosis, coronary
therosclerosis is frequently not associated with ischemia.
uclear myocardial perfusion imaging with single-photon
mission computed tomography (SPECT) is often used for
ssessment of ischemia, and with the modern, hybrid
PECT-CT systems, the coronary calcium score can be
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Highlights From JACC 2010 January 25, 2011:480–514erived from the CT part, whereas the SPECT part
rovides information on myocardial perfusion and ischemia
214). A drawback is that SPECT imaging with current
ystems is time consuming. Novel, high-speed SPECT
ystems have been developed that permit data acquisition of
min and 2 min for stress and rest images, respectively
215). A head-to-head comparison between conventional
nd high-speed SPECT in 63 patients demonstrated similar
etection of ischemia by high-speed SPECT in one-seventh
f the conventional acquisition time. The high reproduc-
bility and quantitative nature makes high-speed SPECT a
ery attractive method to assess myocardial ischemia (216).
Although ischemia is mainly related to obstructive lesions
n the large epicardial vessels, microvascular disease is also
mportant, particularly in women. Pepine et al. (217)
eported on the prognostic value of coronary microvascular
eactivity. At 5.4 years of follow-up, reduced coronary flow
eserve (2.32, measured by Doppler flow wire and aden-
sine) was related to adverse outcome.
In patients presenting to the emergency room with the
uspicion of an ACS, SPECT imaging was used with the
ovel tracer -methyl-p-[123I]-Iodophenyl-pentadecanoic
cid (BMIPP) (218). A total of 507 patients were enrolled
n 50 centers; these patients received BMIPP within 30 h of
nset of chest pain. The sensitivity for diagnosing an ACS
as 71%; moreover, BMIPP SPECT added incremental
alue over the clinical data for diagnosis of an ACS at an
arly stage.
Integrated imaging with positron emission tomography
PET) and CT was explored for visualization of vascular
nflammation (219). In this proof-of-concept study, 6 pa-
ients with active vasculitis and 9 asymptomatic control
atients underwent PET-CT with [11C]-PK11195, a se-
ective ligand for peripheral benzodiazepine receptors ex-
ressed in activated macrophages, which is used to visualize
ascular inflammation. High tracer uptake in arterial walls
aorta, carotid arteries) was shown in the symptomatic
ubjects, but not in the asymptomatic subjects. Of interest,
lasma levels of inflammatory biomarkers could not differ-
ntiate between symptomatic and asymptomatic subjects.
In patients with CAD and reduced LV function, predic-
ion of long-term outcome is important. In 603 patients
ith previous infarction and LV dysfunction from the
ALIANT (Valsartan in Acute Myocardial Infarction
rial) echo study, global systolic strain and strain rate were
etermined (220). Whereas longitudinal and circumferen-
ial strain rate were predictive for death or recurrent heart
ailure, only circumferential strain rate was predictive for LV
emodeling. Possibly, strain imaging can also eventually be
sed for prediction of sudden cardiac death (221), which is
mportant in post-infarction patients with reduced LV
unction. Currently, patients with LVEF 30% to 35%
ave a class I indication for an ICD. How often sudden
ardiac death occurs in patients with LVEF 35% was
valuated in 4,865 patients who previously underwent myo-
ardial perfusion SPECT imaging; the median LVEF was c6% (222). Over a median follow-up of 6.5 years, 161
3.3%) sudden deaths occurred, and the extent of perfusion
efects on SPECT was associated with sudden death;
hether SPECT perfusion could be of value for benefit
rom ICD implantation in patients with LVEF 35%
eeds further study (223).
Although radionuclide myocardial perfusion imaging is a
aluable diagnostic tool, the studies require considerable
ime. Chang et al. (224) studied whether a normal stress-
nly SPECT would retain its ability to predict prognosis. In
hat study, 8,034 patients underwent a stress-only SPECT
rotocol, and manifested a comparable annual mortality rate
s another 8,000 patients who underwent rest and stress
esting. In addition, the stress-only group received 61%
ower pharmaceutical dosage. In an accompanying editorial,
skandrian (225) opined that stress-only myocardial perfu-
ion imaging represented a new paradigm in this diagnostic
esting modality.
The increasing use of cardiac imaging has prompted the
evelopment of appropriate-use criteria, which were as-
essed in regard to SPECT by Hendel et al. (226) in a
ulticenter study. Six clinical sites enrolled data regarding
atients undergoing SPECT into an online form, 93% of
hom were successfully assigned an appropriate criteria.
nappropriate use of SPECT was found in 14.4% of
atients, with women and younger patients more prevalent.
hus, this study showed that appropriate-use criteria could
e readily applied in the clinical setting and would point out
reas in which the selection of imaging could be improved.
The question of the prognostic value of CT angiography
CTA) remains uncertain. Chow et al. (227) followed up
,076 consecutive patients who underwent cardiac CT.
ultivariate analysis showed that CAD severity was a
redictor of MACE in that LVEF had incremental value
ver this parameter. Thus, using CTA, CAD severity and
VEF and total plaque score have prognostic and incre-
ental value over routine clinical prognosticators. In an
ccompanying editorial, Mark and Kong (228) commented
hat although the data from Chow et al. (227) are encour-
ging, the ability of CTA to provide “actionable” informa-
ion will await the results of the major soon-to-be-
ndertaken PROMISE (Prospective Multi-Center Imaging
tudy for Evaluation of Chest Pain) trial.
Cardiovascular imaging in JACC this year was remarkable
ot only for the introduction to practicing cardiologists and
ranslational CV investigators of methods that are ripe for
se in discovery, but also for the publication of a series of
mportant articles on myocardial injury characterization by
RI delayed enhancement and its potential utilization in
tate-of-the-art clinical cardiology. Indeed, in the last year,
series of articles defined the state of the art, in terms of
easuring the area at risk by imaging the injured myocardial
ass directly in addition to a full characterization of
yocardial necrosis, microvascular damage, and obstruction
n the setting of acute MI. In the first study (229). 100
onsecutive patients with NSTE-ACS underwent MRI
w
t
w
w
e
w
m
r
t
s
a
f
t
d
w
a
r
v
p
n
i
t
i
s
r
t
t
c
t
e
p
i
p
t
v
q
i
i
m
s
b
d
K
fi
S
h
a
o
d
v
y
t
l
c
c
b
t
f
p
d
(
s
t
p
m
c
r
(
f
b
o

c
a
f
h
f
r
t
e
t
m
d
d
a
r
i
g
m
M
p
h
fi
p
t
o
(
i
l
e
t
s
a
M
m
m
505JACC Vol. 57, No. 4, 2011 DeMaria et al.
January 25, 2011:480–514 Highlights From JACC 2010ith T2-weighted edema imaging. The authors showed
hat after adjustment for peak troponin, patients with edema
ere at higher risk of having CV events than patients
ithout edema. They concluded that measuring myocardial
dema identifies reversible injured myocardium and predicts
orse outcome. In a similar study, Eitel et al. (230)
easured the relationship between infarct size and area at
isk by MRI as the myocardial salvage index, and report that
he index correlates well with the prognosis of patients who
uffered acute MI. Conversely, Larose et al. (231) document
strong relationship between infarct volume and late
unctional recovery. Indeed, infarct volume provided impor-
ant incremental benefit for predicting late myocardial
ysfunction, with an area under the curve of 0.92 (p 0.05)
hen compared with traditional markers. The articles were
ccompanied by editorial comments by Klocke (232) and by
eviews of infarct imaging by Kim et al. (233) and micro-
ascular obstruction by Bekkers et al. (234) that define the
resent capabilities of this technology for the clinical phe-
otyping of acute MI.
The long-term effect of cyclosporine A on LV remodel-
ng from the landmark study reported this year illustrates
he power of the foregoing methods not only for the
ndividual post-infarct patient, but also for testing of future
trategies to reduce infarct size and improve ventricular
emodeling. In that study, Mewton et al. (235) examined
he effect of a single dose of cyclosporine administered at the
ime of reperfusion on LV remodeling and function by
ardiac MRI performed 5 days and 6 months after infarc-
ion. The investigators demonstrate that the infarct-limiting
ffect of cyclosporine given at the time of reperfusion
ersists up to 6 months, highlighting the influence of
nflammation and potential reperfusion injury on infarct size
rogression after coronary occlusion.
Along the same lines, JACC has been the main venue for
he demonstration that myocardial damage associated with
entricular overload can be characterized and accurately
uantified by MRI delayed enhancement. This year, an
mportant study (235) fully demonstrated the prognostic
mportance of MRI delayed enhancement in patients with
yocardial overload induced by aortic stenosis. The study
hows that myocardial loss and replacement by fibrosis can
e quantified by MRI delayed enhancement and relates
irectly to prognosis after aortic valve replacement. Indeed,
aplan-Meier analyses revealed that higher degrees of
brosis related to worse long-term all-cause mortality.
imilar relationship could be shown for fibrosis measured by
istopathology. The study also validates the MRI method
gainst fibrosis measured by histopathology from biopsies
btained at the time of valve replacement.
Along similar lines, the relationship between myocardial
amage as demonstrated by contrast-enhanced MRI and
entricular arrhythmias continues to feature among this
ear’s JACC original publications as the knowledge body in
his field augments. This year, Heidary et al. (236) pub-
ished a significant article relating infarct morphology and aharacteristics by delayed enhanced MRI with CV out-
omes. They studied 70 patients with low EF (25  11%)
eing considered for defibrillator placement to characterize
he infarct border zone by delayed enhanced MRI. They
ound that the size of the border zone was larger in the 29
atients who had CV events compared with patients who
id not, whereas infarct core and all other parameters
including EF and LV end-diastolic volume and end-
ystolic volume) were not. They concluded that quantifica-
ion of core and border zones by MRI are important in the
rediction of events after automatic ICD insertion and
ight assist in the management of patients with ischemic
ardiomyopathy. In a related paper, Aquaro et al. (237)
eported an interesting relationship between right ventricle
RV) abnormalities detected by MRI in patients with very
requent premature ventricular contractions (PVCs) of left
undle branch block (LBBB) morphology and clinical
utcomes. They enrolled 440 consecutive patients with
1,000 PVCs of LBBB morphology (minor diagnostic
riterion for arrhythmogenic right ventricular cardiomyop-
thy/dysplasia) and evaluated RV size and function. They
ound that subjects with multiple RV abnormalities were at
igher risk for CV events, suggesting that in subjects with
requent PVCs of LBBB morphology, cardiac MRI allows
isk stratification. The emerging pattern from the results of
hese and other studies indicates that risk stratification
fforts in patients with MI and nonischemic cardiomyopa-
hies may be enriched or even in large part defined by
yocardial damage characterized and quantified by MRI
elayed enhancement.
Several important articles addressed the issue of prognosis
uring stress MRI imaging using dobutamine or adenosine
s modalities. Until recently, the lack of data on prognosis
epresented 1 of the most important obstacles to the clinical
mplementation of these techniques. An article by Koroso-
lou et al. (238) examined myocardial wall motion abnor-
alities and perfusion in 1,493 patients undergoing stress
RI and demonstrated that abnormal wall motion or
erfusion yielded independent prognostic value for both
ard events and late revascularization, surpassing clinical
ndings and those derived from the rest MRI. An accom-
anying an editorial by Hundley et al. (239) concluded that
he technique was reaching maturity for clinical use. More-
ver, contributions from Patel et al. (240) and Neizel et al.
241) push the envelope in this field by studying the
nfluence of perfusion quantification using Fermi deconvo-
ution and regional dysfunction quantification using spatial
ncoded strain imaging, respectively. Both groups found
hat quantification of MRI parameters enhanced the MRI
tress test, highlighting the cutting edge of this technology
t the moment.
Finally, Langham et al. (242) describe a truly unique
RI technique of measuring oxygen saturation in the calf
uscles of patients with PAD. The authors made direct
easurements of oxygen saturation in the femoral/poplitealrteries and veins during cuff-induced reactive hyperemia
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Highlights From JACC 2010 January 25, 2011:480–514ith MR spectroscopy. They found a significantly longer
ashout time, and lower upslope of blood flow, in patients
ith peripheral vascular disease compared with healthy
ontrols. The suggest that post-occlusive transient changes
n venous blood oxygenation might provide a new measure
f vascular competence found to be abnormal in patients
ith PAD.
In an editorial, Nagel (243) discusses the methodology
nd results of a multicenter study performed in Japan using
oronary imaging by MRI. Kato et al. (244) uses a method
hat has been the focus of great interest for nearly 2 decades,
ut has faced important technologic limitations given the
hallenges of imaging such small moving targets by MRI. In
hat study, the investigators studied 138 patients with
uspected CAD from 7 hospitals in Japan in comparison
ith conventional X-ray angiography. They found an en-
ouraging area under the curve value for the patient-based
nalysis (0.87, 95% CI: 0.0.81 to 0.93) using whole-body
RA techniques without contrast. In the CT side, this
ear, the work of Gottlieb et al. (245), using data from the
ore64 trial, highlighted the higher than expected preva-
ence of obstructive coronary lesions among symptomatic
atients with calcium score zero. In that analysis, 291
atients were included, and of those, 72 patients had a
alcium score of zero. Fourteen of these patients had at least
50% stenoses by conventional coronary angiography,
ighlighting the fact that the absence of coronary calcifica-
ion does not exclude obstructive stenosis. The article
teered an ongoing debate about the use of calcium score
ssessment in symptomatic persons with suspected CAD.
lso in the field of coronary imaging by CT, Chow et al.
246) demonstrated that 64-slice multidetector CT coro-
ary angiography provides important prognostic informa-
ion not only in patients presenting to the emergency room
ith chest pain, and typically lower of prevalence of CAD
Hoffman et al. [247]), but also among patients with
stablished CAD or at high risk for CAD. They studied
,076 patients who had CTA and were followed up pro-
pectively for a mean of 16 months. The researchers found
hat using CTA, CAD severity, LVEF, and total plaque
core had incremental prognostic value over routine clinical
redictors, supporting the concept that CTA indeed has
rognostic value over and above diagnostic power.
agnetic resonance imaging. Rijzewijk et al. (248) re-
ort, in patients with type II diabetes mellitus, the relation-
hip between hepatic triglyceride content, measured by
RI, and insulin sensitivity, myocardial function, and
igh-energy phosphate metabolism. Patients with high
evels of hepatic triglycerides had decreased insulin sensitiv-
ty, reduced myocardial perfusion and glucose uptake, and
ower high-energy phosphate stores, compared with patients
ith low hepatic triglyceride content. These findings dem-
nstrate that hepatic steatosis has a strong relationship with
ardiac metabolism and function in patients with type II
iabetes. talvular Heart Disease
fforts in the field of percutaneous prosthetic valve implan-
ation have progressed very rapidly in the last year, partic-
larly with regard to aortic stenosis. Rodes-Cabau et al.
249) reported acute and late outcomes of a Canadian
ulticenter experience with transcatheter aortic valve im-
lantation (TAVI) for aortic stenosis patients at very high
urgical risk. In all, 339 patients underwent procedures, with
success rate of 93.3% and a 30-day mortality of 10.4%. At
median follow-up of 8 months, the mortality rate was
2.1%. Significantly, patients with either porcine aorta or
railty exhibited similar outcomes. Thus, utilizing both
ransfemoral and transapical approaches, these investigators
howed a comparable mortality with TAVI compared with
urgical risk calculators. In an accompanying editorial, Iung
t al. (250) pointed out that this study was performed in 6
enters rather than 1 expert center and utilized standard
valuation protocols including both transapical and trans-
emoral approaches. These factors in addition to the evalu-
tion of the porcine at aorta and frailty were felt to provide
rowing evidence of the ability of TAVI to be a useful
lternative in aortic stenosis patients with very high or
rohibitive surgical risk.
In many patients, the transfemoral approach to TAVI is
ot possible owing to vascular limitations. Therefore, Pasic
t al. (251) reported the use of transapical aortic valve
mplantation in 175 consecutive cases. Technical success
as achieved in 100% of patients; the 30-day mortality was
.1%, and survival at 12 months was 82.6%. Procedures
ere done in a hybrid catheterization laboratory, and the
otential for cardiopulmonary bypass or combined elective
oronary artery stenting was available. The authors con-
luded that, although the transapical approach to TAVI is
till evolving, this appears to be an extremely attractive
pproach and one that requires the integration of a team of
oth surgeons and cardiologists.
An interesting application of TAVI has been in the
etting of a bioprosthetic aortic valve with significant
tenosis or regurgitation (so called valve-in-valve). Khawaja
t al. (252) presented the first series of patients with
egenerative bioprosthetic valves treated with TAVI. These
nvestigators achieved excellent results in patients with
egenerative changes resulting in a valve malfunction. They
onclude that this is a very viable approach in patients with
ioprosthetic valves for whom the risk for direct surgical
ntervention is high.
The prevalence of metabolic syndrome is increasing
ramatically, but it remains uncertain whether this condi-
ion has an adverse effect upon LV geometry and function in
atients with aortic stenosis. Therefore, Page et al. (253)
nalyzed data from the ASTRONOMER (Aortic Stenosis
rogression Observation Measuring Effects of Rosuvasta-
in) study and found that patients with metabolic syndrome
nd aortic stenosis had a higher LV mass index, relative wall
hickness ratio, and prevalence of hypertrophy. They also
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January 25, 2011:480–514 Highlights From JACC 2010anifested lower diastolic and systolic tissue velocities.
hus, metabolic syndrome is independently associated with
ore pronounced LV hypertrophy and worse myocardial
unction in patients with aortic stenosis.
Assessing the severity and prognosis of mitral regurgita-
ion continues to be a challenging problem. Le Tourneau et
l. (254) assessed the impact of left atrial (LA) volume upon
ltimate outcome in 492 patients in sinus rhythm with
itral regurgitation. Adjusting for established prognostica-
ors of outcome, the LA index was independently associated
ith survival after diagnosis (HR: 1.3, p  0.001). Patients
ith LA index of 60 ml/m2 have an increased mortality
ver patients with LA index 40 ml/m2 (HR: 2.8, p 
.016). In an accompanying editorial, Levine and Nattel
255) point out that LA size is elevated in a variety of
onditions and has been considered by many to be the
quivalent of the “body temperature” of the heart. They
mphasize that the current study has demonstrated that LA
ize is a marker of prognosis independent of the severity of
egurgitation and is not an irreversible marker of adverse
rognosis after surgical repair. In a related article, Magne et
l. (256) examined the relationship between symptom-free
urvival and exercise-induced changes in regurgitation and
ulmonary artery pressure in patients with mitral regurgi-
ation. They performed resting and bicycle exercise Doppler
chocardiography with 61 asymptomatic patients who had
oderate or severe mitral regurgitation. During exercise, the
ffective regurgitant orifice and regurgitant volume mark-
dly increased in 32% of patients, which correlated with
hanges in systolic pulmonary artery pressure and were
ccompanied by a lesser symptom-free survival. In an
ccompanying editorial, Flachskampf (257) comments that
hese findings extend the previous observations of the
nvestigators regarding the increase of mitral regurgitation
ith exercise in patients with functional mitral regurgitation
o patients with degenerative regurgitation. However, he
autions that although these data are very robust, it is still
oo early to translate them into clinical practice.
The search for improved prosthetic heart valves contin-
es. In this regard, Schmidt et al. (258) describe work in
rogress on minimally invasive implantation of a living
issue engineered heart valve. The trileaflet heart valves were
abricated from biodegradable synthetic scaffolds and self-
xpanding stents and seeded with autologous vascular or
tem cells. Transapical implantation of these valves was
erformed in sheep. The study demonstrated the feasibility
f merging tissue engineering and minimally invasive valve
eplacement technologies, and may well be a harbinger of
he future of prosthetic heart valves to be used in the clinical
etting.
ipid Disorders
ecretory phospholipase A2 is a family of proatherogenic
nzymes that hydrolyze lipoprotein phospholipids, contrib-
te to cholesterol loading of macrophages, and activate inflammatory pathways. Rosenson et al. (259) conducted a
andomized prospective trial to assess the effects of inhibi-
ion of secretory phospholipase A2 with varespladib versus
lacebo as an adjunct to atorvastatin 80 mg daily. After 8
eeks varespladib/atorvastatin reduced LDL and secretory
hospholipase A2 levels but not major adverse CV events
ompared with placebo at 6 months after randomization.
hus, varespladib did reduce LDL cholesterol and inflam-
atory biomarkers in ACS patients, but did not result in a
eduction of events.
Considerable attention has focused upon the ability to
ncrease HDL in humans. Waksman et al. (260) evaluated
he safety and feasibility of an autologous delipidated HDL
nfusions in patients with ACS. Patients received either 7
eekly HDL-selected delipidated infusions or control
lasma apheresis. The levels of delipidated pre-HDL in the
lasma, the most effective form of HDL for lipid remover
rom arteries, increased from 5.6% to 79%. A trend toward
egression of total atheroma plaque volume by IVUS was
lso identified. Thus, delipidated HDL may provide an
lternate approach to attack the residual risk in patients in
hom LDL reduction has been maximized.
A study that attracted much attention was ARBITER
–HALTS (Arterial Biology for the Investigation of the
reatment Effects of Reducing Cholesterol 6–HDL and
DL Treatment Strategies in Atherosclerosis) trial (261).
his trial studied the effects of adding niacin or ezetimibe to
onventional statin treatment, using carotid intermedial
hickness as the endpoint. Although the initial study was
erminated early, this final report included the 14-month
ollow-up of 208 patients. The addition of niacin therapy
ontinued to show regression of carotid intermedial thick-
ess that was superior to ezetimibe. As this study addressed
he surrogate endpoint, the effect of these agents upon CV
vents and heart endpoints remains uncertain and awaits the
esult of future trials.
Finally, an interesting series of viewpoints and commen-
aries address the question of how soon and how intensively
ipid-lowering therapy should be applied in primary preven-
ion. Steinberg (262) argued that atherosclerosis is a pro-
ressive life-long disease that results in events only later in
ife. It follows, he opined, that treatment earlier in life
ould result in substantial reduction of “life-long” events.
ollowing the same theme, Forrester (263) contends that
urrent guidelines for reduction of LDL cholesterol are too
igh. He points out that “normal” values for lipid levels
erived from population studies are misleading, and that
either other animals nor hunter-gatherer people would
ave such high LDL levels. In addition, LDL levels are low
n childhood and increase progressively during life. Both
uthors point out that virtually all studies of lipid reduction
re of 5 years’ duration, which may underestimate the
verall effect of this therapy. In a commentary on this
rticle, Fletcher and Hulley (264) point out that data are not
vailable to substantiate the contention that earlier or more
ntense lipid-lowering therapy would actually result in
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Highlights From JACC 2010 January 25, 2011:480–514enefits. In addition, the potential for side effects such as
yopathies or rhabdomyolysis could be increased, and the
ost to society would not be inconsiderable. While uncer-
ainty remains and debate continues, it does appear that the
rend is for earlier and more aggressive lipid-lowering
herapy in industrialized societies.
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